

G OPEN ACCESS

Citation: Li X, Zhong X, Wang Y, Zeng X, Luo T, Liu Q (2021) Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS ONE 16(5): e0250602. https://doi.org/10.1371/journal.pone.0250602

Editor: Chiara Lazzeri, Azienda Ospedaliero Universitaria Careggi, ITALY

Received: November 13, 2020

Accepted: April 11, 2021

Published: May 3, 2021

Copyright: © 2021 Li et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its <u>Supporting Information</u> files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: COVID-19, Coronavirus Disease 2019; WHO, World Health Organization; OR, odds ratio; SMD, standard mean difference; COPD, Chronic obstructive pulmonary disease; CKD, **RESEARCH ARTICLE**

Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis

Xinyang Li¹, Xianrui Zhong², Yongbo Wang³, Xiantao Zeng³, Ting Luo¹, Qing Liu⁴*

 School of Stomatology, Wuhan University, Wuhan, Hubei, China, 2 Department of Computer Science, University of Illinois at Urbana-Champaign, Champaign, Illinois, United States of America, 3 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China,
 Department of Epidemiology and Health Statistics, School of Health Sciences, Wuhan University, Wuhan, Hubei, China

* liuqing@whu.edu.cn

Abstract

Objective

We aimed to systematically identify the possible risk factors responsible for severe cases.

Methods

We searched PubMed, Embase, Web of science and Cochrane Library for epidemiological studies of confirmed COVID-19, which include information about clinical characteristics and severity of patients' disease. We analyzed the potential associations between clinical characteristics and acteristics and severe cases.

Results

We identified a total of 41 eligible studies including 21060 patients with COVID-19. Severe cases were potentially associated with advanced age (Standard Mean Difference (SMD) = 1.73, 95% CI: 1.34-2.12), male gender (Odds Ratio (OR) = 1.51, 95% CI:1.33-1.71), obesity (OR = 1.89, 95% CI: 1.44-2.46), history of smoking (OR = 1.40, 95% CI:1.06-1.85), hypertension (OR = 2.42, 95% CI: 2.03-2.88), diabetes (OR = 2.40, 95% CI: 1.98-2.91), coronary heart disease (OR: 2.87, 95% CI: 2.22-3.71), chronic kidney disease (CKD) (OR = 2.97, 95% CI: 1.63-5.41), cerebrovascular disease (OR = 2.47, 95% CI: 1.54-3.97), chronic obstructive pulmonary disease (COPD) (OR = 2.88, 95% CI: 1.89-4.38), malignancy (OR = 2.60, 95% CI: 2.00-3.40), and chronic liver disease (OR = 1.51, 95% CI: 1.06-2.17). Acute respiratory distress syndrome (ARDS) (OR = 39.59, 95% CI: 19.99-78.41), shock (OR = 21.50, 95% CI: 10.49-44.06) and acute kidney injury (AKI) (OR = 8.84, 95% CI: 4.34-18.00) were most likely to prevent recovery. In summary, patients with severe conditions had a higher rate of comorbidities and complications than patients with non-severe conditions.

Conclusion

Patients who were male, with advanced age, obesity, a history of smoking, hypertension, diabetes, malignancy, coronary heart disease, hypertension, chronic liver disease, COPD,

Chronic kidney disease; AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CI, confidence interval. or CKD are more likely to develop severe COVID-19 symptoms. ARDS, shock and AKI were thought to be the main hinderances to recovery.

1. Introduction

Coronavirus Disease 2019(COVID-19) which, was first identified in Wuhan, Hubei Province, China in December 2019, has already swept across the world. The World Health Organization (WHO) has officially declared the outbreak as a pandemic and a public health emergency [1]. As of 9th March 2021, according to WHO, the number of confirmed cases around the world has surged dramatically to 116,166,652 with 2,582,528 deaths, which suggests the general mortality rate is approximately 2.22% [2]. The severity of symptoms among patients infected with COVID-19 varies considerably from being varies considerably from being asymptomatic to being a critical illness with lethal complications [3, 4].

Some researchers have suggested that there are several factors possibly responsible for the severity of COVID-19, such as hypertension, diabetes and smoking [5–7]. Therefore, we performed this systematic review and meta-analysis to explore the potential risk posed by critical medical states in COVID-19 patients. Specifically, in this study we have compared the reported clinical characteristics of patients with non-severe and severe COVID-19 in eligible published literature.

2. Method

2.1 Search strategy

The literature search was performed using international databases PubMed, Embase, Web of science and Cochrane Library using the search terms: ("COVID-19" OR "SARS-Cov-2") AND ("characteristics" OR "clinical"): The specific search strategy is listed in <u>S1 Table</u>. Included studies were published between December 2019 and February 2021. The meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [8].

2.2 Study selection

To minimize bias, two authors (LXY and ZXR) independently screened titles and abstracts and extracted potentially eligible articles. The full texts of selected articles were then carefully assessed according to the inclusion and exclusion criteria. Disagreements were resolved by discussion, with the third researcher (LQ) to reach a consensus.

2.3 Inclusion and exclusion criteria

Inclusion criteria:(1) case-control studies or cohort studies; (2) articles reporting the clinical characteristics and the severity of disease in patients diagnosed with COVID-19; (3) articles reporting the severity of COVID-19 and details of related factors; (4) articles reporting the specific grading standards of the severity of COVID-19.

The definition of severe disease was based on clinical symptoms, i.e., patients having severe dyspnea, extremely low oxygen saturation, respiratory distress or requiring mechanical ventilation, ICU admission or death.

The exclusion criteria: (1) review articles, letters, comments or opinions; (2) samples of less than 50; (3) incomplete information or full texts unavailable.

2.4 Quality assessment

All included studies were retrospective cohort studies so, the Newcastle-Ottawa Scale (NOS) was used to evaluate quality [9]. The major components include: representativeness of the exposed cohort, selection of the non- exposed cohort, ascertainment of exposure, demonstration that outcome of interest was not present at start of study, comparability, assessment of outcome, follow-up time and adequacy of follow up of cohorts. The quality rating is from 0 to 10 stars and the score \geq 7 stars indicates high-quality articles.

2.5 Data extraction

Two independent authors (LXY and ZXR) performed the data extraction by using standardized forms, which included date of publication, authors, region, number of included patients, sex, body mass index (BMI), smoking habits, comorbidities, complications, and severe or nonsevere COVID-19.

2.6 Statistical analysis

We calculated odds ratios (ORs) in the dichotomous variables and standard mean difference (SMD) in the continuous variables with the 95% confidence intervals (CIs) and assessed publication bias using Stata 12.0. Heterogeneity was measured by I² statistic. We used a Mantel-Haenszel random effects model to calculate effect sizes. In order to discover the potential sources of heterogeneity, we performed subgroup analyses and meta-regression analysis according to study location (Hubei province and outside Hubei province) and the median ages of patients. The stability of results was assessed by conducting a sensitivity analysis which omitted each study in turn. Funnel plots were used to assess for publication bias and asymmetry was taken to indicate bias. In this study, *P* values <0.05 were regarded as indicating statistical significance for the summary OR and SMD. In order to quantify the effects of risk factors on COVID-19 patients, we calculated population attributable fraction (PAF) by using the attributable fraction formula:

$$PAF = Pc \times \frac{RR - 1}{RR}$$

where Pc is the prevalence of the risk factors in the population [10]. In this analysis, the ORs were used as approximations of RRs.

3 Results

3.1 Study selection and characteristics

The complete literature-search process is displayed in Fig 1. The search strategy initially retrieved 10314 articles, 10273 of which were excluded by assessing the eligibility criteria. Of these studies, 764 papers were duplicates, 9442 were perceived as unrelated research and 67 articles were in line with exclusion criteria. Finally, 41 articles [11–51] published between February 7th, 2020 and March 13th, 2021 were included, all of which were retrospective cohort studies. In total, 21060 patients were included in the meta-analysis. The characteristics of all the included studies are shown in Table 1.

3.2 Quality evaluation

The results of the quality evaluation of the included retrospective cohort studies are displayed in Table 2. Because of the urgent need for published results on COVID-19 during the



Fig 1. Flow diagram of literature selection.

https://doi.org/10.1371/journal.pone.0250602.g001

outbreak, some studies [11–15, 18, 19, 22, 23, 27, 29, 30, 34, 40, 43, 48, 49, 51] had limited follow up times.

3.3 Summary of the meta-analysis for primary outcomes

We identified 15 risk factors in three categories (demographic characteristics, comorbidities, complications) that have impact on the severity of confirmed cases. All statistically significant factors in our analysis are summarized in Table 3.

3.4 Demographic characteristics

The demographic characteristics including sex, age, smoking history and BMI were pooled for meta-analysis and the results are displayed in Fig 2. There were 39 studies reporting on sex difference, and the pooled result showed that males were more likely to have severe disease than females (OR = 1.51, 95% CI:1.33–1.71; $I^2 = 50.8\%$) [11–18, 20, 22–51]. Advanced age (SMD = 1.73, 95% CI: 1.34–2.12; $I^2 = 98.6\%$) [11–17, 22–24, 26, 29, 31–35, 38, 39, 41–51] was also considered to be a risk factor for severe COVID-19. In all selected studies, the mean age of patients with severe conditions was older than those with non-severe conditions except for the studies from Wang 2020c [35] and Kim 2020 [46]. Patients with a history of smoking were also found to be positively associated with severe disease (OR = 1.40, 95% CI:1.06–1.85; $I^2 = 30.6\%$)

Table 1. Characteristics of the included studies.

Author	Publication Date	Study Location	Samples(M/ F)	Severe	Non- severe	Overall age (Median age/ Mean age, range/SD)	Adjustments
Wang <i>et al</i> . 2020a [11]	Feb 7,2020	Wuhan, China	138(75/63)	36	102	56(42-68)	1,2,4,6,6,7,8,9,0,1,1,1,1,6,6
Zhang <i>et al</i> . 2020a [12]	Feb 19,2020	Wuhan, China	140(71/69)	58	82	57(25-87)	1,2,3,4,5,8,4,6
Guan <i>et al</i> . 2020 [<u>13]</u>	Feb 28,2020	China	1099(640/ 459)	173	926	47(35–58)	1,2,3,4,6,6,7,8,9,0,1,12,8,4,0
Wan <i>et al</i> . 2020 [14]	Mar 21,2020	Chongqing, China	135(73/62)	40	95	47(36–55)	1,2,4,6,8,9,0,2,6,6
Hong <i>et al</i> . 2020 [15]	Apr 24,2020	Daegu, Korea	98(38/60)	13	85	55.4(SD = 17.1)	0,2,4,5,6,7,8,9,0,0,0,0,6,6
Zhang <i>et al</i> . 2020b [<u>16]</u>	Apr 27,2020	Guangdong, China	1350(664/ 686)	229	1121	44.1(SD = 17.9)	0,2,4,5,8
Chen <i>et al</i> . 2020 [17]	Apr 28,2020	Zhejiang, China	145(79/66)	43	102	45.3(SD = 13.6)	0,2,3,4,5,7,8,9,0,10,10,10
Zhao <i>et al.</i> 2020 [18]	Apr 29,2020	Hubei, China	91(49/42)	30	61	46*	0,2,4,5,4,6,6
Zheng <i>et al</i> . 2020 [<u>19]</u>	Apr 30,2020	Hubei, China	73	30	43	43(21-76)	3,5
Hu et al. 2020 [20]	May 3,2020	Wuhan, China	323(166/ 157)	151	172	61(23–91)	1,3,4,5,6,7,8,9,0,1,0,0,4,0
Cai <i>et al</i> . 2020a [21]	May 14,2020	Shenzhen, China	383(183/ 200)	91	292	NA	1
Wang <i>et al</i> . 2020b [22]	May 19,2020	Guangzhou, China	275(134/ 141)	45	230	49(34–62)	1,2,3,4,5,6,7,8,0,1,1,2,13,0
Buckner <i>et al.</i> 2020 [23]	May 22,2020	Seattle, USA	99(53/46)	51	54	69(23–97)	(1,2,3,4,6,7,8,9,0)
Yang <i>et al.</i> 2020 [24]	May 25,2020	Wuhan, China	136(66/70)	33	103	56(44-64)	1,2,4,6,6,7,8,0,2,3,4,6
Feng <i>et al</i> . 2020 [25]	Jun 1,2020	China	476(271/ 205)	124	352	53(40-64)	(1,3,4,5,6,7,8,9,0)
Suleyman <i>et al.</i> 2020 [26]	Jun 16,2020	Detroit, USA	463(165/ 298)	141	214	57.5(16.8)	0,2,3,4,6,7,8,9,@,®,%,%
Cao et al. 2020 [27]	Jun 17,2020	Beijing, China	80(38/42)	27	53	53(SD = 20)	(1,3,4,5,8,9)
Shahriarirad <i>et al.</i> 2020 [28]	Jun 18,2020	Iran	113(71/42)	11	102	53.75(20-99)	1,4,6,6,7,9,1,0
Nie et al. 2020 [29]	Jun 26,2020	Henan, China	671(367/ 304)	72	583	44(31–53)	0,2,3,4,6,8,9
Zhang <i>et al</i> . 2020c [<u>30]</u>	Jul 8,2020	Zhejiang, China	771(394/ 337)	61	710	NA	0,3,4,5,7,8,9,0,6,6
Cai <i>et al</i> . 2020b [<u>31]</u>	Jul 11,2020	Shenzhen, China	298(145/ 153)	240	58	47(33–61)	0,2,4,5,7,8,0,9
Gregoriano <i>et al.</i> 2020 [<u>32</u>]	Jul 15,2020	Switzerland	99(62/37)	35	64	67(56–76)	(0, 0, 4, 5, 7, 8, 9, 0)
Ghweil <i>et al</i> . 2020 [<u>33]</u>	Jul 17,2020	Egypt	66(48/18)	30	36	55.5(SD = 10.1)	1,2,3,4,6,8,19
Yu et al. 2020 [34]	Jul 17,2020	Wuhan, China	1663(838/ 825)	864	799	64(52-71)	(1,2,3,4,5,6,7,8,9,0,0,0)
Wang <i>et al</i> . 2020c [35]	Jul 18,2020	Wuhan, China	483(218/ 265)	421	62	48.4(SD = 12.4)	1,2,3,4,5,7,8,0,2
Lee et al.2020 [36]	Jul 21,2020	Daegu, Korea	694(212/ 482)	137	557	52.1(SD = 18.29)	1,4,5,7,8,9,0,0
Xu et al. 2020 [37]	Jul 25,2020	Wuhan, China	88(36/52)	41	47	57.11(SD = 15.39)	0,4,6,7,8,9

(Continued)

Author	Publication Date	Study Location	Samples(M/ F)	Severe	Non- severe	Overall age (Median age/ Mean age, range/SD)	Adjustments
Wei et al. 2020 [<u>38</u>]	Jul 29,2020	Wuhan, China	276(155/ 121)	14	262	51(41-58)	1,2,3,4,5,6,7,8,9,9,9
Liu et al. 2020 [<u>39</u>]	Aug 5,2020	Jiangsu, China	625(329/ 296)	64	561	44.44(SD = 17.19)	1,2,4,5
Wang <i>et al</i> . 2020d [40]	Aug 25,2020	Wuhan, China	110(48/62)	38	72	NA	1,3,4,6,6
Ishii <i>et al</i> . 2020 [<u>41]</u>	Sep 10,2020	Japan	345(198/ 147)	112	233	54(32-68)	(1,4,5,6,7,8,9,0,0)
Shu et al. 2020 [42]	Sep 14,2020	Wuhan, China	293(135/ 158)	86	207	57.1(SD = 15.6)	(1,2,4,6,6,6,0,0)
Du et al. 2020 [43]	Sep 21,2020	Wuhan, China	164(84/80)	29	135	61.8(SD = 13.6)	1,2,3,4,5,7,8,9,1,19
Xiong <i>et al</i> . 2020 [44]	Oct 22,2020	Wuhan,China	116(60/36)	55	61	58.5(47-69)	1,2,4,5,6,7,8,0, 0,13,4
Lee <i>et al</i> . 2020b [<u>45]</u>	Nov 18,2020	Korea	7339(2970/ 4369)	927	6412	47.1(SD = 19.0)	(1,2,4,6,7,8,9,0)
Kim <i>et al</i> . 2020 [46]	Nov 23,2020	Uzbekistan	843(480/ 363)	150	693	36(26-47)	1,2,4
Ren et al. 2020 [47]	Dec 4,2020	Wuhan, China	129(62/67)	40	89	50(34.5-61)	0,2,4,5,7,8,1
Vial et al. 2020 [48]	Dec 14.2020	Santiago, Chile	88(43/45)	18	70	49(39.5-65)	0,2,3,4,5,9
Lv et al. 2021 [49]	Jan 1,2021	Wuhan, China	409(188/ 321)	48	361	50.47(SD = 12.43)	1,2,4,5,8,9
Zhang <i>et al</i> . 2021a [50]	Jan 1,2021	Jining, China	78(50/28)	6	72	43.82(SD = 15.91)	1,2,3,4,5,6,7,8
Zhang <i>et al</i> . 2021b [51]	Feb 13,2021	Henan, China	172(92/80)	51	121	47.9(SD = 18.3)	(1,2,4,5,6,8,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0

Table 1. (Continued)

* Zhao et al. 2020 [18] only reported median age without age range

①:sex ②:age ③:smoking history④:hypertension⑤:diabetes⑥:cerebrovascular disease ⑦:malignancy ⑧:coronary heart disease ⑨: chronic obstructive pulmonary disease (COPD)⑩:chronic liver disease ⑪: chronic kidney disease (CKD) ⑫: shock⑬: acute respiratory distress syndrome (ARDS) ⑭: acute kidney injury (AKI) ⑮: cardiac trauma ⑮: arrhythmia ⑰: disseminated intravascular coagulation (DIC) ⑲: digestive tract injury ⑲: body mass index (BMI) ⑳: asthma NA: not available

https://doi.org/10.1371/journal.pone.0250602.t001

[12, 13, 17, 19, 20, 22, 23, 25–27, 29, 30, 33, 35, 38, 40, 41, 43, 48, 50]. In studies which reported BMI, we observed higher rates of obesity (BMI \geq 30kg/m²) in patients with severe disease (OR = 1.89, 95% CI: 1.44–2.46; I² = 0.0%) [20, 21, 23, 26, 30, 35].

3.5 Comorbidities

Fig 3 shows the potential association between seven comorbidities and the risk of severe COVID-19 using ORs. Compared with patients having non-severe disease, there was a higher potential for patients having severe conditions to have one or more comorbidities. Results show that CKD had the highest OR value at 2.97 (95% CI: 1.63-5.41; $I^2 = 68.4\%$) [11–13, 17, 20, 22, 25, 26, 28, 30, 32, 34, 36, 41–43, 45, 47, 51], followed by COPD with the OR of 2.88 (95% CI: 1.89-4.38; $I^2 = 52.6\%$) [11–15, 17, 20, 23, 25–30, 32, 34, 36–38, 41, 43, 45, 48, 49, 51]. Other significant outcomes included coronary heart disease (OR: 2.87, 95% CI: 2.22-3.71; $I^2 = 59.9\%$) [11–15, 17, 20, 22–26, 28, 30–32, 34–38, 41, 43], cerebrovascular disease (OR = 2.47, 95% CI: 1.54-3.97; $I^2 = 28.4\%$) [11, 13, 14, 20, 22, 24, 25, 34, 38, 40, 42, 44, 50, 51], hypertension (OR = 2.42, 95% CI: 2.03-2.88; $I^2 = 67.9\%$) [11–18, 20, 22–51], diabetes

Author	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability	Assessment of outcome	Follow- up time	Adequacy of follow- up of cohorts	Total
Wang <i>et al</i> . 2020a [<mark>11</mark>]	\$	*	*	\$	☆	☆		$\stackrel{\sim}{\sim}$	7
Zhang <i>et al.</i> 2020a [12]	\$	*	*	\$	**	☆		${\leftrightarrow}$	8
Guan <i>et al</i> . 2020 [<u>13]</u>	*	*	*	*	☆	☆			6
Wan <i>et al.</i> 2020 [<u>14</u>]	\$	*	*	\$	☆	☆		$\stackrel{\sim}{\sim}$	7
Hong <i>et al.</i> 2020 [<u>15</u>]	*	*	*	*	☆	☆		${\sim}$	7
Zhang <i>et al</i> . 2020b [16]	\$	*	*	\$	☆		*	$\stackrel{\sim}{\sim}$	7
Chen <i>et al</i> . 2020 [17]	*	*	*	*	☆	☆	☆	${\sim}$	8
Zhao <i>et al.</i> 2020 [<u>18]</u>	*	\$	Å	*	\Rightarrow	☆		${\leftrightarrow}$	7
Zheng <i>et al</i> . 2020 [<u>19</u>]	*	*	*	*		☆		${\sim}$	6
Hu et al. 2020 [20]	*	\$	÷.	*	**	☆	\$	☆	9
Cai <i>et al</i> . 2020a [<u>21]</u>	*	\$	×.	*	**	☆	\$	☆	9
Wang <i>et al</i> . 2020b [22]	*	\$	Å	*	\Rightarrow	☆		${\leftrightarrow}$	7
Buckner <i>et al.</i> 2020 [23]	*	\$	Å	*	☆	☆		☆	7
Yang <i>et al</i> . 2020 [24]	*	\$	Å	*	\Rightarrow	☆	\$	${\leftrightarrow}$	8
Feng <i>et al.</i> 2020 [25]	\$	*	*	\$	**	☆	*	$\stackrel{\sim}{\sim}$	9
Suleyman et al. 2020 [26]	\$	*	*	*	**	☆	☆	${\sim}$	9
Cao <i>et al</i> . 2020 [27]	*	*	*	*	☆	☆		${\sim}$	7
Shahriarirad et al. 2020 [28]	*	*	*	*	☆	☆	*	☆	8
Nie <i>et al</i> . 2020 [29]	*	*	*	*	**	☆		${\sim}$	8
Zhang <i>et al</i> . 2020c [30]	*	\$	×.	*	**	☆		☆	8
Cai <i>et al</i> . 2020b [<u>31]</u>	\$	*	*	\$	**	☆	*	$\stackrel{\sim}{\sim}$	9
Gregoriano et al. 2020 [32]	*	\$	*	*	${\leftrightarrow}$	*	\$	\$	8
Ghweil <i>et al.</i> 2020 [33]	*	☆	\$	*	*	*	\$	☆	8
Yu <i>et al</i> . 2020 [34]	*	☆	\$	*	☆	2		☆	7
Wang <i>et al.</i> 2020c [<u>35]</u>	*	☆	\$	*	☆		\$	☆	7

Table 2. Methodological quality evaluation of enrolled studies based on Newcastle-Ottawa (NOS).

(Continued)

Author	Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability	Assessment of outcome	Follow- up time	Adequacy of follow- up of cohorts	Total
Lee <i>et al</i> .2020 [36]	Å	*	\$	Å	*	☆	\$	☆	8
Xu <i>et al</i> . 2020 [37]	X	*	\$		×	☆	\$	\$	7
Wei <i>et al</i> . 2020 [38]	☆	*	☆	☆	**	${\leftrightarrow}$	☆	${\sim}$	9
Liu <i>et al</i> . 2020 [<u>39]</u>	\$	\$	☆	\$	**	☆	\$	☆	9
Wang <i>et al</i> . 2020d [<u>40]</u>	\$	\$	Å	\$	☆	☆		☆	7
Ishii <i>et al</i> . 2020 [41]	*	☆	×	*	**	☆	\$	*	9
Shu <i>et al</i> . 2020 [42]	*	☆	*	*	**	*	\$	*	9
Du <i>et al</i> . 2020 [43]	*	☆	×	*	☆	☆		*	7
Xiong <i>et al</i> . 2020 [44]	*	☆	×	*	☆	☆	\$	*	8
Lee <i>et al.</i> 2020b [<u>45]</u>	*	☆	*	*	**	*	\$		8
Kim <i>et al</i> . 2020 [<u>46</u>]	\$	*	\$	\$	☆	☆	\$	${\leftrightarrow}$	8
Ren <i>et al</i> . 2020 [47]	*	*	☆	*	**	☆	\$	☆	9
Vial <i>et al.</i> 2020 [48]	\$	\$	Å	\$	**	☆		☆	8
Lv et al. 2021 [49]	*	\$	£	*	**	☆			7
Zhang <i>et al</i> . 2021a [50]	*	☆	*	*	*	×	\$	☆	8
Zhang <i>et al</i> . 2021b [51]	2	*	*	2	**	*		*	7

Table 2. (Continued)

https://doi.org/10.1371/journal.pone.0250602.t002

 $(OR = 2.40, 95\% \text{ CI: } 1.98-2.91; \text{ I}^2 = 55.6\%) [11-20, 22-45, 47-51]$ and chronic liver disease $(OR = 1.51, 95\% \text{ CI: } 1.06-2.17; \text{ I}^2 = 0.0\%) [11-15, 17, 20, 22-26, 28, 30-32, 34-38, 41, 43-44, 47, 50]$. While the analyses of asthma $(OR = 1.93, 95\% \text{ CI: } 0.81-4.61; \text{ I}^2 = 79.4\%) [26, 28, 35, 38, 45]$ showed no significant differences between patients with severe and non-severe disease.

3.6 Complications

The results shown in Fig 4 indicate that ARDS (OR = 39.59, 95% CI: 19.99–78.41; $I^2 = 48.7\%$) [11, 13–15, 17, 20, 22, 24, 26, 44], shock (OR = 21.50, 95% CI: 10.49–44.06; $I^2 = 27.4\%$) [11, 13, 15, 17, 20, 22, 24, 43, 44, 51] and AKI (OR = 8.84, 95% CI: 4.34–18.00; $I^2 = 40.7\%$) [11, 13–15, 18, 20, 24, 26, 44, 51] which are potential life-threatening conditions, were clearly responsible for the ICU admissions. Additionally, some other complications like DIC (OR = 29.75, 95% CI: 3.41–259.68; $I^2 = 0.0\%$) [13, 22], secondary infection (OR = 10.03, 95% CI: 1.99–50.55; $I^2 = 39.0\%$) [14, 25], arrhythmia (OR = 9.80, 95% CI:3.91–24.60; $I^2 = 0.0\%$) [11, 12] and cardiac trauma (OR = 7.38, 95% CI:2.28–23.82; $I^2 = 75.0\%$) [11, 14, 15, 18, 24, 51] also potentially increase the severity of COVID-19. Though we lacked sufficient evidence to support the results

, 1 ,			
Risk Factors	Number of Studies	OR (95%CI)	I ²
Acute respiratory distress syndrome	10	39.59 (19.99-78.41)	48.7%
Shock	11	21.50 (10.49-44.06)	27.4%
Acute kidney injury	10	8.84 (4.34–18.00)	40.7%
Chronic kidney disease	17	2.97 (1.63–5.41)	68.4%
Chronic obstructive pulmonary disease	24	2.88 (1.89-4.38)	52.6%
Coronary heart disease	33	2.87 (2.22–3.71)	59.9%
Malignancy	25	2.60 (2.00-3.40)	11.9%
Cerebrovascular disease	16	2.47 (1.54–3.97)	28.4%
Hypertension	39	2.42 (2.03–2.88)	67.9%
Diabetes	39	2.40 (1.98–2.91)	55.6%
Obesity	7	1.89 (1.44–2.46)	0.0%
Advanced age	30	1.73 (1.34–2.12)	98.6%
Chronic liver disease	15	1.51 (1.06–2.17)	0.0%
Male	39	1.51 (1.33–1.71)	50.8%
Smoking history	20	1.40 (1.06–1.85)	30.6%

Table 3. Results of the meta-analysis for primary outcomes.

https://doi.org/10.1371/journal.pone.0250602.t003

for these other complications except for shock, ARDS and AKI, the data we already had were of high consistency. However, some complications such as hypohepatia (OR = 1.53, 95% CI: 0.71-3.30; I² = 0.0%) [18, 24] did not show obvious association with the severity of patients' conditions.

3.7 Population attributable risk

We calculated the population attributable risk (PAR) of the population infected with COVID-19. PAR reflects the proportion of severe COVID-19 that can be attributed to exposure to a risk factor. Table 4 shows that the PARs ranged from 0.9% to 11.3%, with the estimated attributable fraction in COVID-19 patients being 11.3% for hypertension and 7.1% for obesity. It is suggested that up to 11.3% and 7.1% of severe cases could have been avoided if the prevalences of hypertension and obesity were reduced.

3.8 Subgroup analysis and meta-regression analysis

We performed subgroup analyses to identify the possible sources of heterogeneity of some outcomes. We tried to analyze several factors such as study location, publication date, sample size and patients' average age of which study location gave a relatively meaningful result as shown in Table 5. This shows high consistency among the studies conducted in Hubei province but the heterogeneity of the studies outside Hubei province is also significant. Interestingly, the studies conducted in Hubei province show the ORs of ARDS was much lower than other regions. The meta-regression analysis demonstrates that the association between coronary heart disease and increased severity was influenced by age (P = 0.013), and the discrepancy between patients' median ages in eligible studies partly contributed to the heterogeneity. (Fig 5)

3.9 Sensitivity analysis and publication bias

By excluding every article in turn, we conducted a sensitivity analysis and there was no evident change in either the significant outcomes or in heterogeneity. To assess the risk of publication bias, we drew a funnel plot for each factor. The results, displayed in S1 Fig, show that nearly all

(A) Sex		(B) Age
Study ID	0R (95% CI) Wei	Study nt % SMD (95% CI) Weight
Wang et al. 2020a Chang et al. 2020a Guan et al. 2020a Wang et al. 2020b Hong et al. 2020b Zhao et al. 2020b Wang et al. 2020b Weit	1.45 (0.67, 3.16) 1.99 1.53 (0.78, 3.01) 2.22 0.98 (0.71, 1.37) 4.60 0.91 (0.44, 1.92) 2.02 1.42 (0.44, 1.92) 2.02 1.42 (0.44, 1.92) 2.02 1.63 (1.46, 2.62) 4.33 0.665 (0.27, 1.56) 1.57 1.96 (1.62, 3.06) 3.66 1.55 (0.81, 2.95) 2.42 1.33 (0.83, 3.02) 1.85 1.39 (1.63, 3.04) 2.18 1.39 (0.83, 3.02) 1.85 1.39 (1.63, 3.04) 2.18 3.19 (1.65, 2.46) 3.30 2.95 (0.80, 5.26) 1.41 1.94 (0.24, 3.76) 0.33 1.19 (0.72, 1.95) 3.27 1.59 (0.93, 2.74) 2.98 2.55 (1.42, 4.75) 2.63 3.37 (1.35, 1.77) 3.47 1.56 (0.32, 1.77) 3.47 1.50 (0.39, 1.77) 3.47 2.02 (0.62, 6.60) 0.96 1.40 (0.42, 2.27) 8.48 3.02 (1.79, 5.11) 3.10 2.47 (1.05, 5.80) 1.63 1.01 (0.44, 2.22) 1.85 1.01 (0.44, 2.22) 1.85 1.01 (0.44, 2.21) 1.85 1.20 (0.92, 2.15) 1.33 1.20 (0.92, 2.15) 1.33 1.20 (0.92, 2.15) 1.33 1.21 (0.94, 2.22) 1.35 1.21 (0.95, 2.15) 1.33 1.21	Wang et al. 2020a 3.10 (2.67, 3.63) 3.27 Guan et al. 2020a 0.93 (0.58, 1.29) 3.38 Guan et al. 2020a 3.80 (3.03, 4.17) 3.24 Wan et al. 2020a 0.65 (0.68, 1.29) 3.86 Wan et al. 2020a 0.65 (0.68, 1.29) 3.86 Wan et al. 2020a 0.53 (0.06, 1.12) 3.22 Chan et al. 2020b 0.54 (0.08, 1.09) 3.46 Wan et al. 2020b 0.53 (0.07, 0.89) 3.88 Wang et al. 2020b 0.53 (0.17, 0.89) 3.23 Subgryphane et al. 2020 0.53 (0.17, 0.89) 3.23 Subgryphane et al. 2020b 2.56 (2.07, 3.06) 3.23 Gregoriano et al. 2020b 1.02 (0.59, 1.46) 3.33 Gregoriano et al. 2020b 1.02 (0.59, 1.46) 3.33 Gregoriano et al. 2020b 1.02 (0.59, 1.46) 3.33 Shu et al. 2020b 1.02 (0.76, 1.29) 3.23 Shu et al. 2020b 1.02 (0.76, 1.29) 3.23 Shu et al. 2020b 1.02 (0.76, 1.29) 3.23 Shu et al. 2020b 1.02 (0.76, 1.29) 3.33 Sh
Zhang et al. 2021a Zhang et al. 2021b	3.00 (0.33, 27.06) 0.31 1.36 (0.70, 2.64) 2.35	-6.15 0 6.15
Overall (I-squared = 50.8%, p = 0.000) • NOTE: Weights are from random effects analysis - 0353 1	1.51 (1.33, 1.71) 100.	0
(C) Smoking history		(D) BMI
Study	% OR (95% CI) Weid	Study %
Zhang et al. 2020a	3.04 (0.73, 12.69) 3.18	ID OR (95% CI) Weight
Guan et al. 2020 Chen et al. 2020	1.89 (1.26, 2.84) 14.87 0.56 (0.15, 2.10) 3.65 0.44 (0.08, 2.35) 2.41	Hu et al. 2020 1.87 (0.60, 5.84) 5.48
Hu et al. 2020 Wang et al. 2020b	2.77 (1.35, 5.71) 8.76 0.38 (0.02, 6.86) 0.87	Cai et al. 2020a 2.28 (1.16, 4.49) 15.50 Buckner et al. 2020 129 (0.59, 2.81) 11.79
Buckner et al. 2020	0.94 (0.36, 2.48) 5.92 1.85 (0.97, 3.54) 9.97	Suleyman et al. 2020 1.65 (0.99, 2.75) 27.00
Cao et al. 2020	9.04 (0.96, 85.43) 1.41 2.75 (0.54, 13.88) 2.56	Zhang et al. 2020c 2.39 (1.34, 4.26) 21.31 Wang et al. 2020c 1.63 (0.64, 4.13) 8.22
Chang et al. 2020c	1.26 (0.48, 3.29) 5.99 0.76 (0.27, 2.14) 5.36 1.74 (0.96, 3.18) 10.78	Du et al. 2020 Overall (I-squared = 0.0%, p = 0.888) 2.14 (0.95, 4.84) 10.70 1.89 (1.44, 2.46) 100.00
Wei et al. 2020	1.51 (0.32, 7.13) 2.76 0.33 (0.10, 1.05) 4.49 0.76 (0.08, 6.00) 1.45	NOTE: Weights are from random effects analysis
Zhang et al. 2021a	2.20 (0.22, 22.03) 1.45 1.40 (1.06, 1.85) 10.00	.171 1 5.84
NOTE: Weights are from random effects analysis		
0117 1	85.4	



https://doi.org/10.1371/journal.pone.0250602.g002

the funnel plots are symmetrical except for cerebrovascular disease, which suggests the risk of publication bias is low in our analysis.

4 Discussion

This study has examined the potential risk factors of severe COVID-19 such as demographic characteristics, comorbidities and complications to assist clinicians with allocation of medical resources. The higher the ORs of the risk factors, the greater the risks they bring. Our analysis has shown that males, obese patients (BMI ≥ 30 kg/m²), patients with advanced age or a smoking history faced a greater risk of having severe COVID-19. This finding has also been supported by some previous studies [52–54]. However, some of the results of one meta-analysis were not consistent with our analysis, since they found gender irrelevant to the severity of COVID-19, which may possibly be due to the relatively small sample size [55]. The comorbidities including hypertension, diabetes, CKD, coronary heart disease, COPD, cerebrovascular disease and chronic liver disease could probably aggravate the illness and this outcome was consistent with other studies. [5, 7, 55–57] Complications including shock, AKI and ARDS

(A) Chronic kidney disease			(B) Chronic obstructiv	ve pulmon	ary disea	se
Study	OR (95% CI)	% Weight	Study ID		OR (95% CI)	% Weight
	OR (55% CI)	weight	Wang et al. 2020a		9.18 (0.92, 91.31)	2.54
Vang et al. 2020a	2.94 (0.40, 21.69) 7 30 (0.34, 154.96)	4.69	Zhang et al. 2020a	100	7.30 (0.34, 154.96)	1.60
Guan et al. 2020	3.24 (0.77, 13.68)	6.25	Wan et al. 2020		7.25 (0.29, 181.90)	1.46
Chen et al. 2020	1.19 (0.11, 13.49)	3.76	Hong et al. 2020		0.87 (0.04, 17.86) 0.17 (0.01, 3.10)	1.63
Wang et al. 2020b	16.36 (1.66, 161.04)	4.04	Hu et al. 2020 Buckner et al. 2020	*	15.41 (0.86, 275.91)	1.76
Feng et al. 2020	2.87 (0.40, 20.59) 0.90 (0.38, 2.13)	4.76	Feng et al. 2020	-	5.47 (2.24, 13.39)	7.12
Shahriarirad et al. 2020	0.65 (0.03, 12.22)	2.92	Cao et al. 2020		0.16 (0.01, 3.01)	1.72
Zhang et al. 2020c	2.35 (0.27, 20.44) 1.02 (0.41, 2.55)	4.31	Shahriarirad et al. 2020 Nie et al. 2020		1.17 (0.13, 10.38) 1.08 (0.24, 4.83)	2.75 4.50
Yu et al. 2020	0.86 (0.42, 1.76)	8.58	Zhang et al. 2020c		59.71 (2.83, 1258.02	2)1.61
Lee et al. 2020a	16.72 (1.85, 150.83) 7.52 (2.39, 23.63)	4.23	Yu et al. 2020		1.39 (0.83, 2.32)	9.07
Shu et al. 2020	→ 22.64 (1.21, 425.14)	2.93	Lee et al. 2020a Xu et al. 2020		4.11 (0.57, 29.45) 3.63 (0.36, 36.35)	3.18 2.53
Du et al. 2020	4.21 (1.65, 10.73) 9.95 (5.58, 17.74)	7.89	Vei et al. 2020 -		8.57 (1.51, 48.76)	3.75
Ren et al. 2020	- 16.71 (0.84, 331.43)	2.86	Du et al. 2020	<u> </u>	2.54 (0.71, 9.09)	5.34
Zhang et al. 2021b	0.78 (0.03, 19.47)	2.57	Vial et al. 2020	<u> </u>	4.64 (2.96, 7.29) 4.47 (0.82, 24.34)	3.88
NOTE: Weights are from random effects analysis			Lv et al. 2021 Zhang et al. 2021b	•	2.43 (0.76, 7.79) 0.17 (0.01, 3.12)	5.82
.00235 1	425		Overall (I-squared = 52.6%, p = 0.001)	\$	2.88 (1.89, 4.38)	100.00
			00079 1	12	58	
(C) Coronary heart disease			(D) Malignancy			
Study		%	(D) Iviangnancy			96
ID	OR (95% CI)	Weight	ID		OR (95% CI)	Weight
Vang et al. 2020a	2.76 (1.03, 7.35)	3.40	Wang et al. 2020a	-	2.00 (0.53, 7.54)	3.64
Guan et al. 2020	3.27 (1.47, 7.27)	4.09	Guan et al. 2020		2.31 (0.59, 9.02) 2.28 (0.22, 23.71)	3.47 1.25
Hong et al. 2020	0.24 (0.01, 4.32)	0.70	Chen et al. 2020		4.93 (0.43, 55.84)	1.17
Chen et al. 2020	- 7.24 (0.29, 181.18)	0.58	Wang et al. 2020		5.20 (0.32, 84.78)	0.82
Wang et al. 2020b	5.73 (2.56, 12.86) 1.28 (0.14, 11.76)	4.05	Buckner et al. 2020 Yang et al. 2020		2.69 (0.86, 8.40) 1.04 (0.10, 10.37)	4.80 1.30
Yang et al. 2020	0.79 (0.36, 1.75) 7.41 (1.74, 31.57)	4.12 2.14	Feng et al. 2020		4.15 (1.29, 13.33)	4.58
Peng et al. 2020 Suleyman et al. 2020	2.50 (1.27, 4.92) 1.62 (1.02, 2.58)	4.61 5.55	Shahrianirad et al. 2020		2.94 (0.11, 76.50)	0.66
Cao et al. 2020	2.18 (0.57, 8.32) 4.29 (1.09, 16.84)	2.38 2.31	Zhang et al. 2020c Cai et al. 2020b		12.19 (2.41, 61.75) 4.25 (0.59, 30.83)	2.52
Nie et al. 2020	1.05 (0.48, 2.29) 1.30 (0.16, 10.42)	4.16	Gregoriano et al. 2020		3.75 (1.01, 13.87)	3.74
Cai et al. 2020b	5.49 (2.35, 12.81) 1.04 (0.40, 2.67)	3.89	Vu et al. 2020 Wang et al. 2020c		2.02 (0.76, 5.34) 0.61 (0.03, 11.09)	0.82
Ghweil et al. 2020	0.39 (0.02, 9.88)	0.57	Lee et al. 2020a	<u>+</u>	1.13 (0.41, 3.11)	5.89
Wang et al. 2020c	12.22 (2.84, 52.52)	2.12	Wei et al. 2020	*	10.00 (0.85, 117.55)	1.13
Xu et al. 2020	1.59 (0.33, 7.54)	1.93	Du et al. 2020	•	1.25 (0.55, 2.82) 1.44 (0.37, 5.61)	8.32 3.49
Ishii et al. 2020	12.70 (3.27, 49.30) 6.77 (2.59, 17.70)	3.47	Xiong et al. 2020	+ *	- 10.75 (0.57, 204.34) 4 28 (3 09, 5 94)	0.80
Du et al. 2020	3.65 (1.41, 9.42) 3.05 (1.15, 8.08)	3.51 3.42	Ren et al. 2020	•	1.67 (0.50, 5.63)	4.27
Xiong et al. 2020	4.41 (1.34, 14.49) 4.09 (3.32, 5.04)	2.75 6.50	Zhang et al. 2021a Overall (I-squared = 11.9%, p = 0.293)	\$	2.17 (0.09, 50.16) 2.60 (2.00, 3.40)	0.71 100.00
Ren et al. 2020	4.63 (0.41, 52.63) 1.75 (0.79, 3.87)	0.95 4.11	NOTE: Weights are from random effects analysis			
Zhang et al. 2021a Zhang et al. 2021b	0.58 (0.03, 11.31) 13.46 (3.64, 49.75)	0.67	.00423 1		236	
Overall (I-squared = 59.9%, p = 0.000)	2.87 (2.22, 3.71)	100.00	(F) Hypertension			
00552 1	1					
.00006	181		Study			%
(E) Cerebrovascular disease	181		Study ID		OR (95% CI)	% Weight
(E) Cerebrovascular disease	181	%	Study ID Wang et al. 2020a Zhang et al. 2020a		OR (95% CI) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94)	% Weight 2.37 2.62
(E) Cerebrovascular disease	181 OR (95% CI)	% Weight	Study ID Wang et al. 2020a Zhang et al. 2020a Guan et al. 2020 Wan et al. 2020		OR (95% Cl) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94) 2.00 (1.34, 2.98) 1.06 (0.31, 3.67)	% Weight 2.37 2.62 3.84 1.42
(E) Cerebrovascular disease	181 OR (95% CI) 20.20 (2.34, 174.44	% Weight	Study UD Ward et al. 2020a Zhang et al. 2020a Guan et al. 2020a Wan et al. 2020a Hong et al. 2020a Zhang et al. 2020a Zhang et al. 2020b		OR (95% CI) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94) 2.00 (1.34, 2.98) 1.06 (0.31, 3.67) 1.50 (0.45, 5.03) 4.04 (2.74, 5.95)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89
(E) Study D Wang et al. 2020a Guane et al. 2020a T T T T T T T T T T T T T	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24)	% Weight)4.14 10.64	Study ID Wang et al. 2020a Zhang et al. 2020a Own et al. 2020a Own et al. 2020a Hong et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b		OR (95% Cl) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94) 1.06 (0.31, 3.67) 1.50 (0.45, 5.03) 4.04 (2.74, 5.95) 1.81 (0.71, 4.63) 2.48 (0.86, 7.10)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76
(E) Cerebrovascular disease	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20)	% Weight)4.14 10.64 2.18	Study Jung et al. 2020a Chang et al. 2020a Construction Guan et al. 2020a Construction Chang et al. 2020b Construction Zhang et al. 2020b Construction Zhang et al. 2020b Construction Hung et al. 2020b Construction Hung et al. 2020b Construction Hung et al. 2020b Construction		OR (95% Cl) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94) 2.00 (1.34, 2.98) 1.06 (0.31, 3.67) 1.50 (0.45, 5.03) 4.04 (2.74, 5.95) 1.81 (0.71, 4.63) 2.48 (0.86, 7.10) 2.65 (1.64, 4.28) 3.59 (1.79, 7.19)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74
(E) Cerebrovascular disease	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.88 (0.19, 3.87)	% Weight)4.14 10.64 2.18 7.33	Study D Up D Uhang et al. 2020a - Guare et al. 2020a - Wan et al. 2020a - Uman et al. 2020a - D'amag et al. 2020b - D'amag et al. 2020b - D'amag et al. 2020b - Uman et al. 2020b - Uman et al. 2020b - Buckner et al. 2020b - Buckner et al. 2020b -		OR (95% Cl) 5.09 (2.26, 11.48) 1.88 (0.91, 3.94) 2.00 (1.34, 2.88) 1.06 (0.31, 3.67) 1.50 (0.45, 5.03) 4.04 (2.74, 5.35) 1.81 (0.71, 4.33) 2.48 (0.86, 7.10) 2.85 (1.64, 4.28) 3.59 (1.79, 7.19) 0.88 (0.45, 2.14) 4.70 (2.20, 10.94)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.47 2.28
(E) Cerebrovascular disease Study Wang et al. 2020a Goum et al. 2020 Hong et al. 2020 Wang et al.	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9.955 (0.13, 240, 26)	% Weight 10.64 2.18 7.33 5.97 2.01	Study D Veng et al. 2020a Construct et al. 2020a Guan et al. 2020a D Van et al. 2020a D Johns et al. 2020a D Van et al. 2020a D		OR (95% Cl) 5.09 (2.26, 11.48) 1.89 (0.91, 3.94) 2.00 (1.34, 2.88) 1.06 (0.31, 3.67) 1.50 (0.45, 5.03) 4.04 (2.74, 5.95) 1.81 (0.71, 4.63) 2.46 (0.86, 7.10) 2.65 (1.64, 4.28) 3.59 (1.79, 7.19) 0.88 (0.45, 2.14) 4.70 (2.02, 10.94) 1.82 (1.15, 2.87) 1.69 (1.03, 2.77)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.47 2.28 3.62 3.47
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guane et al. 2020a Hong et al. 2020a Hu et al. 2020 Hu et al. 2020 Hu et al. 2020 Hu et al. 2020 Hang et al. 2020b Hang et al. 2020b Han	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) ⇒ 9.55 (0.38, 240.26) 3.37 (1.27, 8.93)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02	Study D Vang et al. 2020a Cabar et al. 2020a Guar et al. 2020a Cabar et al. 2020a Dang et al. 2020a Cabar et al. 2020a Zhang et al. 2020a Cabar et al. 2020a Yang et al. 2020a Cabar et al. 2020a Feng et al. 2020a Cabar et al. 2020a Cabar et al. 2020a Cabar et al. 2020a Status et al. 2020a Cabar et al. 2020a		OR (95% CI) 5.09 (2.26, 11.48) 1.89 (0.91, 3.84) 1.06 (0.31, 3.87) 1.06 (0.31, 3.87) 1.05 (0.46, 5.03) 4.04 (2.74, 4.28) 1.05 (0.46, 5.03) 4.04 (0.46, 7.10) 2.85 (1.64, 4.28) 3.59 (1.79, 7.19) 0.88 (0.45, 2.14) 4.70 (2.02, 10.94) 1.82 (1.15, 2.87) 0.40 (0.12, 1.35) 1.69 (1.03, 2.77)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.47 2.28 3.62 3.47 1.46 1.33
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guan et al. 2020 Hu et al. 2020 Yang et al. 2020 Feng et al. 2020 Yang et a	181 OR (95% Cl) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9.95 (0.38, 240.26) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18	Study Judy UN Values of al. 2020a Chang et al. 2020a Control of al. 2020a Guare et al. 2020a Control of al. 2020a Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Control of al. 2020b Wang et al. 2020b Eucline ret al. 2020b Study man et al. 2020b Eucline ret al. 2020b Subsymmet et al. 2020b Subsymmet et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b Zhang et al. 2020b		OR (95% CI) 509 (2.26, 11.48) 1.89 (0.91, 3.94) 1.60 (0.31, 3.67) 1.50 (0.43, 2.98) 1.60 (0.31, 3.67) 1.50 (0.45, 5.03) 1.61 (0.31, 3.67) 1.51 (0.44, 5.03) 2.65 (1.64, 4.28) 5.59 (1.77, 7.19) 0.98 (0.45, 2.14) 1.62 (1.52, 2.87) 1.62 (1.62, 2.87)	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.28 3.62 3.47 1.46 1.33 2.00 3.13
(E) Cerebrovascular disease Study ID Wang et al. 2020a Hong et al. 2020b Wang et al. 2020b Wang et al. 2020b Feng et al. 2020b Viet al. 2020b Wei et al. 2020b Wei et al. 2020b	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) >> 55 (0.38, 240.26) 3.37 (1.27, 8.93) 1.28 (0.75, 2.03) 3.85 (0.38, 36.34)	% Weight)4.14 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7 20	Study Judy UP Judy UP Judy Guar et al. 2020 Judy Guar et al. 2020 Judy Zhang et al. 2020 Judy Vang et al. 2020 Judy Burdiner et al. 2020 Judy Fring et al. 2020 Shahninining et al. 2020 Shahninining et al. 2020 Judy Cao et al. 3020 Judy Cao et al. 302		OR (59% CI) 500 (226, 11.46) 1.86 (5.47, 13.46) 1.00 (1.34, 2.56) 1.00 (1.35, 2.76) 1.00 (1.35, 2.76)	% Weight 2.37 2.62 3.84 1.42 3.89 2.03 1.76 3.53 2.74 2.28 3.62 3.47 1.46 1.33 2.00 3.13 2.80 3.13 2.82 2.33
(E) Cerebrovascular disease Study ID Wang et al. 2020a Goum et al. 2020 Wang et	181 OR (95% Cl) 20.20 (2.34, 174, 44 1.96 (0.82, 6.24) 1.24 (0.06, 2.74) 2.83 (0.47, 14.80) 9.55 (0.38, 240.26) 3.37 (1.27, 8.33) 1.28 (0.75, 2.19) 3.85 (0.43, 36.34) 1.46 (0.31, 6.88) 1.198 (2.53, 56.70)	% Weight)4.14 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04	Study Theory Theory </td <td></td> <td>OR (55% CI) 500 (224, 11.44) 1200 (134, 2.36) 1200 (134, 2.36) 1006 (133, 3.67) 1500 (045, 5.03) 140 (274, 5.95) 141 (071, 4.63) 140 (274, 5.95) 141 (071, 4.63) 144 (274, 5.95) 141 (071, 4.63) 144 (274, 5.95) 141 (071, 4.63) 145 (274, 5.95) 141 (274, 5.95) 144 (274, 5.95) 144 (274, 5.14) 143 (275, 5.95) 144 (274, 5.14) 144 (</td> <td>% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.247 2.28 3.62 3.47 1.46 1.33 2.00 3.13 2.82 2.33 1.27 4.39</td>		OR (55% CI) 500 (224, 11.44) 1200 (134, 2.36) 1200 (134, 2.36) 1006 (133, 3.67) 1500 (045, 5.03) 140 (274, 5.95) 141 (071, 4.63) 140 (274, 5.95) 141 (071, 4.63) 144 (274, 5.95) 141 (071, 4.63) 144 (274, 5.95) 141 (071, 4.63) 145 (274, 5.95) 141 (274, 5.95) 144 (274, 5.95) 144 (274, 5.14) 143 (275, 5.95) 144 (274, 5.14) 144 (% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.247 2.28 3.62 3.47 1.46 1.33 2.00 3.13 2.82 2.33 1.27 4.39
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guane et al. 2020a Hong et al. 2020b Wang et al	181 OR (95% Cl) 20.20 (2.34, 174, 44 1.96 (0.82, 6.24) 1.24 (0.06, 27, 20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.35 (0.43, 36, 20, 26) 3.35 (0.43, 36, 20, 26) 3.35 (0.43, 36, 20, 26) 3.36 (0.43, 36, 20) 3.36 (0.43, 36, 20) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.35 (0.43, 36, 20) 3.36 (0.43, 46, 20) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.36 (0.43, 46, 20) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.37 (1.27, 8.93) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.37 (1.27, 8.93) 3.57 (1.04, 7.5, 9.9) 3.57 (1.04, 7.5, 7.5, 7.5, 7.5, 7.5, 7.5, 7.5, 7.5	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23	Study D Vang et al. 2020a Canag et al. 2020a Guar et al. 2020a Canag et al. 2020a Darrow et al. 2020a Canag et al. 2020a Charrow et al. 2020a Canag et al. 2020a Charrow et al. 2020a Canag et al. 2020a Mang et al. 2020b Canag et al. 2020b Wang et al. 2020b Canag et al. 2020b Subsymmet et al. 2020b Canag et al. 2020b Subsymmet et al. 2020b Canag et al. 2020b Privang et al. 2020b Canag et al. 2020b Vang et al. 2020b Canag et al. 2020b University Canag et a		$\begin{array}{c} {\rm OR} \ (89\% \ {\rm CI}) \\ 500 \ (2.26, 11.46) \\ 1.50 \ (0.31, 3.67) \\ 1.50 \ (0.31, 3.67) \\ 1.50 \ (0.43, 2.50) \\ 1.50 \ (0.44, 5.63) \\ 1.50 \ (0.4$	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.89 2.03 1.76 3.83 2.74 2.47 2.47 2.47 2.48 3.62 3.47 1.46 3.43 2.00 3.13 2.82 2.33 4.27 2.47 2.47 2.47 2.47 2.47 2.47 2.47
(E) Cerebrovascular disease Study jo Vang et al. 2020a Guan et al. 2020a Hong et al. 2020b Vang et al.	181 OR (95% CI) 20.20 (2.34, 174, 44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 174.80) 2.83 (0.47, 174.80) 3.37 (1.27, 8.93) 3.37 (1.27, 8.93) 1.28 (0.75, 2.19) 3.85 (0.43, 38.34) 1.46 (0.31, 6.88) 1.18 (2.53, 56.70) 8.75 (1.04, 73.59) 1.53 (0.07, 32.91)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20	Study Judy UN Values of al. 2020a Chang et al. 2020a Calast et al. 2020a Calast et al. 2020a Calast et al. 2020a Zhang et al. 2020b Calast et al. 2020a Zhang et al. 2020b Calast et al. 2020b Zhang et al. 2020b Calast et al. 2020b Values et al. 2020b Calast et al. 2020b Study et al. 2020b Eucline et al. 2020b Subsymmet et al. 2020b Subsymmet et al. 2020b Subsymmet et al. 2020b Calast et al. 2020b Subsymmet et al. 2020b Subsymmet et al. 2020b Value et al. 2020b Subsymmet et al. 2020b Value et al. 2020b Value et al. 2020b		OR (59% CI) 5.00 (2.26, 11.49) 1.80 (9.11.32) 2.00 (1.34, 2.39) 1.50 (9.14, 3.2) 1.50 (9.45, 8.03) 1.41 (0.71, 4.50) 2.45 (1.64, 4.20) 2.45 (1.64, 4.20) 2.45 (1.64, 4.20) 2.45 (1.64, 4.21) 1.45 (1.15, 2.87) 1.65 (1.64, 2.14) 1.65 (1.64, 2.14) 1.6	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 1.76 3.53 2.74 2.28 3.62 3.62 3.47 1.43 3.62 3.47 1.43 2.00 3.13 2.82 2.33 1.27 4.39 1.27 1.25 1.27 1.25 1.27 1.25 2.62 3.42 1.42 1.42 1.42 1.42 1.42 1.42 1.42 1
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guan et al. 2020 Hong et al. 2020 Wang et al. 2020 Yang et al. 2020 Yang et al. 2020 Yang et al. 2020 Wang et	181 OR (95% CI) 20 20 (2 34, 174 44 1.24 (0.62, 7.24) 1.24 (0.62, 7.24) 2.63 (0.47, 14.80) 3.57 (1.27, 8.93) 1.28 (0.75, 2.19) 3.56 (0.43, 358) 1.28 (0.75, 2.19) 3.56 (0.43, 358) 1.58 (0.63, 355, 56.70) 8.75 (1.04, 73.59) 1.53 (0.07, 32.91) 1.53 (0.07,	% Weight)4.14 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02	Study Theory et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Ware et al. 2020a Theory et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Theory et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Theory et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Theory et al. 2020a We et al. 2020a Theory e		OR (59% CI) 5.00 (2.26, 114) 5.00 (2.26, 114) 5.00 (2.26, 114) 5.00 (2.26, 114) 5.00 (2.26, 114) 5.00 (2.11, 3.27) 5.00	% Weight 2.37 2.62 3.84 1.42 1.47 3.89 2.03 3.89 2.03 2.74 2.47 2.47 2.47 2.47 2.47 2.47 2.47
Wang et al. 2020a # Guann et al. 2020a # Hong et al. 2020a # Yang et al. 2020b # Yang et al. 2020b # Yang et al. 2020b # Yu et al. 2020b	181 OR (95% CI) 20.20 (2.34, 174.44 1.24 (0.62, 5.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9.55 (0.38, 240.26) 3.37 (1.27, 8.33) 1.28 (0.75, 2.19) 3.55 (0.47, 3.59) 1.58 (0.44, 6.04) 2.47 (1.54, 3.97)	% Weight)4.14 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02 100.00	Study D Vang et al. 2020a 2 Jang et al. 2020a 0 Class et al. 2020a 0 Jang et al. 2020a 0 Zhang et al. 2020a 0 Zhang et al. 2020a 0 Zhang et al. 2020b 0 Zhang et al. 2020b 0 Zhang et al. 2020b 0 Parte et al. 2020b 0 Zhang et al. 2020b 0 Zhang et al. 2020b 0 Caso et al. 2020b 0 Ver et al. 2020b 0		OR (95% CI) 5.00 (226, 114) 1.80 (0.51, 3.14) 2.00 (0.31, 3.20) 2.00 (0.31, 3.20) 1.50 (0.44, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.94) 4.06 (274, 5.95) 4.04 (274, 5.95) 4.04 (274, 5.95) 4.04 (274, 5.95) 4.06 (274, 5.95) 4.06 (274, 5.95) 5.00 (45, 214) 4.70 (1.44, 5.23) 4.70 (1.44, 5.23) 5.26 (1.64, 4.26) 5.26 (1.64, 4.26) 5.26 (1.64, 4.26) 5.26 (1.64, 4.26) 5.26 (1.64, 4.26) 7.70 (1.64, 4.26) 7.72 (1.54, 3.16) 5.86 (3.44, 9.84) 7.72 (1.54, 3.74) 5.86 (3.44, 9.84) 7.72 (1.54, 3.74) 5.86 (3.44, 9.84) 5.86 (3.44, 9	% Weight 2.37 2.62 3.84 1.42 3.89 2.03 3.89 2.03 2.74 2.47 2.47 2.47 2.47 2.47 2.47 2.47
Wang et al. 2020a Image: Construct of the second seco	181 OR (95% CI) 2020 (2.34, 174.44) 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 2.63 (0.47, 14.80) 9.55 (0.03, 240.26) 3.37 (1.27, 8.83) 1.28 (0.75, 2.19) 3.55 (0.43, 36.34) 1.46 (0.31, 6.88) 11.98 (2.53, 56.70) 1.53 (0.44, 73.59) 1.53 (0.44, 73.59) 1.53 (0.47, 3.57) 1.53 (0.44, 3.97)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02 100.00	Study Jung et al. 2020a Umag et al. 2020a Jung et al. 2020a Guar et al. 2020a Jung et al. 2020a Damag et al. 2020a Jung et al. 2020a Damag et al. 2020a Jung et al. 2020a Damag et al. 2020b Jung et al. 2020b Damag et al. 2020b Jung et al. 2020b Damag et al. 2020b Jung et al. 2020b Vang et al. 2020b Jung et al. 2020b Suberginant et al. 2020b Jung et al. 2020b Suberginant et al. 2020b Jung et al. 2020b Care et al. 2020b Jung et al. 2020b Une et al. 2020b Jung et al. 2020b Verag et al. 2020b Jung et al. 20		OR (95% CI) 5.00 (226, 114) 5.00 (226, 114) 5.00 (226, 114) 5.00 (247, 154) 5.00 (247,	% Weight 2.37 2.62 3.84 1.42 2.03 1.76 3.84 1.47 3.89 2.03 1.76 3.73 2.74 2.28 3.47 2.28 3.47 2.28 3.47 2.28 3.47 2.28 3.47 2.28 3.47 2.28 3.47 1.46 1.35 3.13 3.13 3.21 3.75 3.27 4.39 3.25 3.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1
American Strategy American Strategy Study Image: Strategy Ub Image: Strategy Wang et al. 2020a Image: Strategy Hong et al. 2020a Image: Strategy Wang et al. 2020b Image: Strategy Wang et al. 2020b Image: Strategy Yang et al. 2020b Image: Strategy Wang et al. 2020b Image: Strategy Yang et al. 2021b Image: Strategy Yang et al. 2021b Image: Strategy Yang et al. 2021b Image: Strategy Yorker Image: Strategy Yorker Image: Strategy Yorker Image: Strategy Yorker Strategy Yorker	181 OR (95% CI) 20.20 (2.34, 174.44 1.36 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 18.33) 2.83 (0.47, 18.33) 3.87 (1.27, 8.33) 1.28 (0.43, 36.34) 1.46 (0.31, 6.88) 1.1.86 (2.53, 56.70) 1.53 (0.07, 32.91) 1.53 (0.44, 6.04) 2.47 (1.54, 3.37)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02 100.00	Study Jung et al. 2020a Unag et al. 2020a Game et al. 2020a Guar et al. 2020a Game et al. 2020a Chang et al. 2020a Chang et al. 2020a Zhang et al. 2020b Chang et al. 2020b Chang et al. 2020b Chang et al. 2020b Zhang et al. 2020b Chang et al. 2020b Wang et al. 2020b Elucioner et al. 2020b Studyman et al. 2020b Chang et al. 2020b Subsymmet et al. 2020b Thang et al. 2020b Thang et al. 2020b Thang et al. 2020b We et al. 2020b Studyman et al. 2020b We et al. 2020b Thang et al. 2020b We et al. 2020b Studyman et al. 2020b We et al. 2020b Thang et al. 2020b We et al. 2020b Studyman et al. 2020b Shu et al. 2020b		OR (59% CI) 5.00 (226, 114, 34) 2.00 (134, 2.20) 2.00 (134, 2.2	% Weight 2.37 2.62 2.63 1.42 2.33 1.47 3.89 1.47 3.89 2.74 2.28 2.33 3.47 2.247 2.28 2.347 2.247 2.28 2.347 2.247 2.28 2.247 2.28 2.247 2.28 2.247 2.28 2.247 2.247 2.28 2.47 2.49 2.49 2.49 2.49 2.49 2.49 2.49 2.49
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guan et al. 2020 Hong et al. 2020 Wang et al. 2020 Yang et al. 2020 Yang et al. 2020 Yang et al. 2020 Yang et al. 2020 Wang et	181 OR (95% CI) 20 20 (2 34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9.85 (0.33, 35, 240.26) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.35 (0.43, 358) 1.58 (0.53, 56.70) 8.75 (1.04, 73.59) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.54 (0.	% Weight 10.64 2.18 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02 100.00	Budy D Wang et al. 2020a 223mag et al. 2020a Wang et al. 2020a D Wang et al. 2020a D Damag et al. 2020a D Unit of et al. 2020a D Diamag et al. 2020a D Cao et al. 2020a D Diamag et al. 2020a D Cao et al. 2020a D Offword et al. 2020a D Vie et al. 2020a		$\begin{array}{c} {\sf OR} (85\% CI) \\ {\sf 5.09} (2.26, 11.484) \\ {\sf 1.59} (0.51, 3.144) \\ {\sf 1.59} (0.51, 3.144) \\ {\sf 1.59} (0.51, 3.144) \\ {\sf 1.59} (0.51, 3.167) \\ {\sf 1.59} (0.44, 5.03) \\ {\sf 1.59} (0.44, 5.04) \\$	% Weight 2.37 2.62 3.7 2.62 3.7 3.84 4.7 3.8 3.8 4.1 4.2 9.7 3.8 3.8 4.1 4.2 9.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.8 5.7 3.7 5.7 3.8 5.7 5.7 3.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5.7 5
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guan et al. 2020 Wang et	181 OR (95% CI) 20.20 (2.34, 174.44 1.24 (0.06, 27.20) 2.65 (0.19, 3.87) 2.63 (0.47, 14.80) ⇒ 3.55 (0.38, 240.26) 3.57 (1.27, 8.33) 1.28 (0.75, 2.19) 3.55 (0.31, 6.83) 1.28 (0.75, 2.19) 3.55 (0.47, 3.59) 1.58 (0.44, 6.04) 2.47 (1.54, 3.97) 2.40 OR (95% CI)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 4.23 2.20 9.02 100.00	Budy Judy Unage et al. 2020a Judy et al. 2020a Clamer et al. 2020a Judy et al. 2020a Damer et al. 2020a Judy et al. 2020a Zhang et al. 2020a Judy et al. 2020a Parte et al. 2020a Judy et al. 2020a Zhang et al. 2020a Judy et al. 2020a Case et al. 2020a Judy et al. 2020a Zhang et al. 2020a Judy et al. 2020a Case et al. 2020a Judy et al. 2020a Ver et al. 2020a Judy et al. 2020a V		OR (95% CI) 5.00 (226, 114, 94) 1.80 (95, 13, 94) 2.00 (034, 136) 1.50 (94, 13, 94) 1.50 (94, 8, 633) 4.04 (274, 136) 4.04 (274, 136) 3.60 (144, 124) 4.70 (124, 136) 3.60 (144, 124) 4.70 (124, 136) 3.64 (146, 147) 4.70 (124, 137) 3.64 (146, 147) 3.64 (147, 147) 3.65 (147, 147) 3.66 (147, 147)	% Weight 2:37 2:62 37 2:62 37 3:84 4:52 37 3:84 4:52 3:62 4:52 3:62 4:52 3:62 4:52 3:62 4:52 3:62 4:52 4:52 4:52 4:52 4:52 4:52 4:52 4:5
Generation Study Study Image: Study U Wang et al. 2020a Guann et al. 2020 Image: Study U/And et al. 2020 Image: Study Wang et al. 2020 Image: Study Wei et al. 2020 Image: Study Yu et al. 2020 Image: Study Shu et al. 2020 Image: Study Zhang et al. 2020 Image: Study Jonetal et al. 2020 Image: Study Jonetal et al. 2020 Image: Study Shu et al. 2020 Image: Study Jonetal (I-squared = 28.4%s, p = 0.152) Image: Study NOTE: Weights are from random effects analysis Jouet 1 Jouet 1 Image: Study Jouet 1 Image: Study	181 OR (95% CI) 2020 (2.34, 174.44) 196 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9.55 (0.03, 240.26) 3.37 (1.27, 8.83) 1.28 (0.75, 2.19) 3.35 (0.43, 36.34) 1.46 (0.31, 6.88) 11.98 (2.53, 56.70) 4.57 (1.04, 73.59) 1.53 (0.44, 73.59) 1.53 (0.47, 3.97) 240 OR (95% CI) 4.57 (1.45, 14.28)	% Weight 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.06 4.23 2.20 9.02 100.00	Budy D UP Vang et al. 2020a Clame et al. 2020a Clame et al. 2020a Clame et al. 2020a Clame et al. 2020a Charne et al. 2020a Clame et al. 2020a Wang et al. 2020b Transport et al. 2020a Subergman et al. 2020a Clame et al. 2020a Subergman et al. 2020a Clame et al. 2020a Call et al. 2020a Clame et al. 2020a Call et al. 2020a Clame et al. 2020a Vang et al. 2020a Clame et al. 2020a </td <td></td> <td>OR (95% CI) 5.00 (226, 114) 5.00 (226, 114) 5.00 (226, 114) 5.00 (226, 114) 5.00 (247, 586) 5.00 (247,</td> <td>% Weight 2.37 2.62 2.42 2.42 2.42 2.44 2.43 3.44 2.43 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.42 2.43 3.69 2.43 2.43 2.43 2.43 2.43 2.45 2.45 2.45 2.45 2.45 2.45 2.45 2.45</td>		OR (95% CI) 5.00 (226, 114) 5.00 (226, 114) 5.00 (226, 114) 5.00 (226, 114) 5.00 (247, 586) 5.00 (247,	% Weight 2.37 2.62 2.42 2.42 2.42 2.44 2.43 3.44 2.43 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.49 2.03 3.42 2.43 3.69 2.43 2.43 2.43 2.43 2.43 2.45 2.45 2.45 2.45 2.45 2.45 2.45 2.45
(E) Cerebrovascular disease Study ID Wang et al. 2020a Goann et al. 2020a Goann et al. 2020a Goann et al. 2020b Wang et	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 2.63 (0.47, 14.80) 3.87 (1.37, 6.33) 1.28 (0.47, 14.80) 3.85 (0.43, 363.40 3.85 (0.43, 363.40) 3.85 (0.43, 363.40) 3.85 (0.43, 363.40) 1.53 (0.07, 32.91) 1.53 (% Weight 10.64 2.18 7.33 5.97 2.01 13.02 2.1.8 3.95 7.04 4.23 9.02 100.00 9.02 100.00	Study Jung et al. 2020a Vang et al. 2020a Jung et al. 2020a Guan et al. 2020a Jung et al. 2020a Chan et al. 2020a Jung et al. 2020a Zhang et al. 2020b Jung et al. 2020b Zhang et al. 2020b Jung et al. 2020b Jung et al. 2020b Jung et al. 2020b Wang et al. 2020b Jung et al. 2020b Jung et al. 2020b Jung et al. 2020b Subsymmet al. 2020b Jung et al. 2020b Subsymmet al. 2020b Jung et al. 2020b Chang et al. 2020b Jung et al. 2020b Vere et al. 2020b Jung et al. 2020b Gregorithmo et al. 2020b Jung et al. 2020b Vere et al. 2020b Jung et al. 2020b <		OR (95% CI) 5.00 (226, 11, 48) 1.80 (91, 32, 20) 1.80 (91, 32, 20) 1.80 (91, 32, 20) 1.80 (91, 32, 20) 1.80 (94, 8, 03) 1.81 (97, 14, 85) 2.85 (1.84, 42) 1.81 (97, 14, 85) 2.85 (1.84, 42) 1.82 (1.15, 2.87) 1.86 (1.84, 22) 1.82 (1.15, 2.87) 1.86 (1.84, 22) 1.82 (1.15, 2.87) 1.86 (1.84, 22) 1.82 (1.15, 2.87) 1.86 (1.44, 15, 15, 2.87) 1.86 (1.44, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15	% Weight 2.37 2.62 2.37 2.62 2.37 2.62 2.37 2.62 2.37 2.62 2.37 2.62 2.37 2.62 2.74 2.43 9 2.03 3.62 2.74 2.39 2.03 3.62 2.33 3.64 2.33 3.64 2.33 3.64 2.33 3.64 2.33 3.64 2.33 3.26 1.27 4.39 3.32 3.26 1.27 4.39 3.32 3.26 1.27 4.39 3.32 3.26 2.25 4.63 3.32 2.29 2.65 3.30 4.25 3.25 3.25 3.25 3.25 3.25 3.25 3.25 3
Cerebrovascular disease Study Vang et al. 2020a Guan et al. 2020 Hong et al. 2020 Yang et al. 2021 Zhang et al. 2021a Yang et al. 2021a You et al. 2021a YOUTE You et al. 2021a You et al. 2021b YOUTE You et al. 2021b You et al. 2021b You et al. 2021b You et al. 2021b You et al. 2020	181 OR (95% CI) 2020 (2 34, 174.44 1.24 (0.62, 7.24) 2.52 (0.62, 5.24) 1.24 (0.06, 27.20) 2.63 (0.47, 14.80) 3.37 (1.27, 6.83) 1.28 (0.75, 2.19) 3.95 (0.33, 5240.26) 3.37 (1.27, 6.83) 1.28 (0.75, 2.19) 3.95 (0.43, 55.67, 70) 8.75 (1.04, 73.59) 1.53 (0.46, 6.04) 2.47 (1.54, 3.97) 240 OR (89% CI) 0.05 (2.73, 3.49) 3.89 (0.27, 3.59) 3.89 (0.27, 3.59) 3.8	% Weight 10.64 2.18 3.95 7.06 4.23 100.00 % Weight 1.97 2.29 1.05 1.51 1.51 1.51 1.51	Budy Jung et al. 2020a Jung e		OR (95% CI) 5.00 (226, 11, 48) 1.80 (5, 13, 24) 2.06 (0, 33, 167) 1.50 (0, 45, 603) 4.04 (274, 5, 633) 4.04 (274, 5, 633) 4.04 (274, 5, 636) 4.04 (274, 5, 636) 5.04 (164, 5, 747) 4.06 (174, 174, 174, 174, 174, 174, 174, 174,	% Weight 237 2.82 3.84 4.389 2.03 3.04 3.142 2.142 2.142 2.147 2.28 3.47 3.14 3.14 3.14 3.14 3.14 3.14 3.14 3.14 3.14 3.14 3.21 3.14 3.34 3.21 3.24 3.
Acceleration Acceleration Study Wang et al. 2020a Wang et al. 2020a Image: Comparison of the state of the	181 OR (95% CI) 20.20 (2.34, 174.44 1.26 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 9. 9.55 (0.38, 240.25) 3.37 (1.27, 8.33) 1.28 (0.75, 2.19) 3.35 (0.43, 6.04) 1.58 (0.44, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 4.57 (1.44, 14.28) 3.17 (1.44, 14.28) 2.47 (1.54, 3.97) 2.40 OR (95% CI) 4.57 (1.44, 14.28) 3.17 (1.44, 14	% Weight 10.64 2.18 3.95 7.06 4.23 100.00 % Weight 1.97 2.29 100.00	Budy Divergent al. 2020a Vange et al. 2020a Caller et al. 2020a Class et al. 2020a Caller et al. 2020a Change et al. 2020a Caller et al. 2020a Vive et al		OR (95% CI) 5.00 (226, 11.48) 1.80 (2.91, 324) 2.06 (134, 126) 1.50 (2.45, 324) 2.06 (134, 126) 1.50 (2.45, 6.03) 4.04 (2.74, 5.93) 4.04 (2.74, 5.93) 4.06 (2.74, 5.93) 4.06 (2.74, 5.93) 4.06 (2.74, 5.93) 4.06 (2.74, 5.93) 4.07 (2.74, 10.94) 4.07 (2.74, 10.94) 5.08 (2.64, 2.34) 5.08 (2.64, 2.34	% Weight 2.37 3.84 1.42 1.42 2.82 3.84 1.42 2.03 3.55 1.42 2.03 3.55 1.42 2.03 3.55 1.42 2.03 3.55 1.42 2.47 3.45 1.42 2.47 3.45 2.47 3.45 2.47 3.45 2.47 3.45 2.43 3.45 2.55 3.45 2.43 3.45 2.55 3.45 2.55 3.45 2.55 3.45 2.55 3.45 3.55 3
Cercbrovascular disease Study Study UD Wang et al. 2020a Guan et al. 2020a Guan et al. 2020a Wang et al. 2020b Wang et al. 2021b Oxter Upped et al. 2021b Oxter Upped et al. 2020b Wang et al. 2020b Upped et al. 2020b <td>181 OR (95% CI) 20.20 (2.34, 174.44) 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 14.80) > 9.55 (0.38, 240.26) 3.37 (1.27, 8.33) 1.28 (0.47, 14.80) > 3.55 (0.38, 240.26) 1.38 (0.44, 6.83) 1.18 (0.44, 6.25, 56.70) 1.53 (0.44, 6.25, 56.70) 1.53 (0.44, 73.59) 1.53 (0.44, 6.23, 56.37) 1.53 (0.44, 6.3, 37) 240 OR (95% CI) 4.57 (1.46, 14.28) 1.39 (0.65, 16.337) 2.46 (0.68, 6.05) 1.26 (0.68, 6.05) 1.27 (0.68, 16.80) 2.46 (0.68, 6.05) 2.54 (0.68, 6.05) 1.52 (0.68, 16.80) 2.54 (0.68, 6.05) 2.54 (0.68, 6.05) 2.54 (0.68, 4.721)</td> <td>% Weight 10.64 2.18 5.97 2.01 21.18 3.95 7.06 7.04 4.23 9.02 100.00 % Weight 1.97 4.12 2.20 9.02 100.00</td> <td>Budy Divergent al. 2020a Damp et al. 2020a Divergent al. 2020a Guar et al. 2020a Divergent al. 2020a Damp et al. 2020b Divergent al. 2020a Damp et al. 2020b Divergent al. 2020b Damp et al. 2020b Divergent al. 2020b Damp et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Subsymmet et al. 2020b Divergent al. 2020b Pareg et al. 2020b Divergent al. 2020b Viewig et al. 2020b Divergent al. 2020b Divergent al. 2020b Divergent al. 2020b Diver</td> <td></td> <td>OR (95% CI) 5.00 (226, 11, 48) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 14, 220) 1.80 (2, 14, 220) 1.80 (2, 14, 220) 1.80 (1, 14, 15, 231) 1.80 (1, 14, 15, 237) 1.80 (1, 14, 15, 157) 1.80 (1, 14, 1</td> <td>% Weight 2.37 2.372 3.84 1.472 2.162 3.84 1.472 2.162 3.84 2.162 2.384 2.162 2</td>	181 OR (95% CI) 20.20 (2.34, 174.44) 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 14.80) > 9.55 (0.38, 240.26) 3.37 (1.27, 8.33) 1.28 (0.47, 14.80) > 3.55 (0.38, 240.26) 1.38 (0.44, 6.83) 1.18 (0.44, 6.25, 56.70) 1.53 (0.44, 6.25, 56.70) 1.53 (0.44, 73.59) 1.53 (0.44, 6.23, 56.37) 1.53 (0.44, 6.3, 37) 240 OR (95% CI) 4.57 (1.46, 14.28) 1.39 (0.65, 16.337) 2.46 (0.68, 6.05) 1.26 (0.68, 6.05) 1.27 (0.68, 16.80) 2.46 (0.68, 6.05) 2.54 (0.68, 6.05) 1.52 (0.68, 16.80) 2.54 (0.68, 6.05) 2.54 (0.68, 6.05) 2.54 (0.68, 4.721)	% Weight 10.64 2.18 5.97 2.01 21.18 3.95 7.06 7.04 4.23 9.02 100.00 % Weight 1.97 4.12 2.20 9.02 100.00	Budy Divergent al. 2020a Damp et al. 2020a Divergent al. 2020a Guar et al. 2020a Divergent al. 2020a Damp et al. 2020b Divergent al. 2020a Damp et al. 2020b Divergent al. 2020b Damp et al. 2020b Divergent al. 2020b Damp et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Marge et al. 2020b Divergent al. 2020b Subsymmet et al. 2020b Divergent al. 2020b Pareg et al. 2020b Divergent al. 2020b Viewig et al. 2020b Divergent al. 2020b Divergent al. 2020b Divergent al. 2020b Diver		OR (95% CI) 5.00 (226, 11, 48) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 13, 220) 1.80 (2, 14, 220) 1.80 (2, 14, 220) 1.80 (2, 14, 220) 1.80 (1, 14, 15, 231) 1.80 (1, 14, 15, 237) 1.80 (1, 14, 15, 157) 1.80 (1, 14, 1	% Weight 2.37 2.372 3.84 1.472 2.162 3.84 1.472 2.162 3.84 2.162 2.384 2.162 2
(E) Cerebrovascular disease Study ID Wang et al. 2020a Gounn et al. 2020 Wang et al. 2020b Yang et al. 2020b Yang et al. 2020b Yang et al. 2020b Yang et al. 2020b Wang et al. 2020b Coverall (I-squared = 26.4%, p = 0.152) NOTE: Weights are from random effects arabysis Note: Weights are fro	181 OR (95% CI) 20 20 (2 34, 174 44 1.24 (0.62, 7.24) 2.5 (0.62, 6.24) 1.24 (0.06, 27, 20) 2.6 (0.47, 14.80) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.36 (0.43, 358) 3.56 (0.43, 358) 3.56 (0.43, 358) 3.56 (0.43, 358) 1.58 (0.07, 52.91) 1.53 (0.07, 52.91) 1.54 (0.07, 52.91) 1.54 (0.07, 52.91)	% Weight 10.64 2.18 5.97 2.01 13.02 21.18 3.95 7.06 7.04 4.23 2.20 9.02 100.00 % Weight 1.97 4.55 1.02 2.22 9.02 100.00	Budy Tweng et al. 2020a Wang et al. 2020a Tweng et al. 2020a Wang et al. 2020a Tweng et al. 2020a Damag et al. 2020a Tweng et al. 2020a Case et al. 2020a Tweng et al. 2020a Vers et al. 2020a Tweng et al. 20		OR (95% CI) 5.00 (226, 11, 48) 1.80 (0.51, 320 1.60 (0.51, 320 1.71 (0.14) (0.50 (0.51, 320 1.71 (0.14) (0.50 (0.51, 320 1.71 (0.14) (0.50 (0.51, 320 1.71 (0.14) (0.51, 320 1.72 (0.61, 41, 305) 1.24 (0.15, 1.75, 320 1.24 (0.15, 1.75, 320 1	% Weight 2.37 2.42 2.42 2.42 2.42 2.42 2.42 2.43 2.03 3.53 2.74 2.24 2.247 2.28 2.47 2.28 3.457 2.247 2.28 3.53 2.747 1.33 3.53 3.13 2.252 2.437 2.283 3.647 1.433 3.753 2.437 2.237 2.237 2.237 2.437 2.237 2.437 2.437 3.457 1.433 3.453 3.453 2.437 2.437 3.457 1.433 3.453 3.453 3.453 3.453 3.453 3.453 3.453 3.453 3.457 1.433 3.454 3.453 3.453 3.454 3.453 3.453 3.4545 3.454 3.454 3.454 3.4
(E) Cerebrovascular disease Study ID Wang et al. 2020a Guan et al. 2020 Hong et al. 2020 Yang et al. 2020 Zhang et al. 2020 Yang et al. 2020 Zhang et al. 2020 Yang	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.85 (0.19, 3.87) 2.85 (0.13, 8.240.26) 3.95 (0.47, 1.8.83) 1.26 (0.07, 52.19) 3.95 (0.43, 55.67.70) 8.75 (1.04, 73.59) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.53 (0.46, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.43, 1.58) 3.95 (0.45, 1.53) 3.95 (0.45, 1.53) 3.95 (0.45, 1.53) 3.95 (0.45, 1.53) 3.95 (0.45, 1.53)	% Weight 10,414 10,64 7,33 5,97 7,06 7,06 7,06 7,06 7,06 7,06 7,06 7,0	Budy Wang et al. 2020a Wang et al. 2020a Construction Charler et al. 2020a <t< td=""><td></td><td>OR (95% CI) 5.00 (226, 11, 48) 1.80 (9.1, 32) 2.00 (0.31, 3.67) 1.50 (9.4, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.06 (144, 214) 4.70 (145, 247) 4.70 (147, 137) 5.80 (147, 147) 5.80 (147, 147)</td><td>% Weight 2.37 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 3.82 2.74 3.82 2.74 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.84 2.74 1.46 3.82 2.74 1.46 3.84 2.74 2.83 3.82 2.83 3.84 2.83 3.81 2.84 2.83 3.81 2.84 2.83 3.81 2.84 2.83 3.81 2.84 2.84 2.84 2.84 2.85 3.84 2.84 2.84 2.85 3.84 2.84 2.85 3.84 2.84 2.85 3.84 2.84 2.83 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.99 3.24 4.29 5.2</td></t<>		OR (95% CI) 5.00 (226, 11, 48) 1.80 (9.1, 32) 2.00 (0.31, 3.67) 1.50 (9.4, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.06 (144, 214) 4.70 (145, 247) 4.70 (147, 137) 5.80 (147, 147) 5.80 (147, 147)	% Weight 2.37 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 1.42 2.62 3.84 3.82 2.74 3.82 2.74 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.82 2.74 1.46 3.84 2.74 1.46 3.82 2.74 1.46 3.84 2.74 2.83 3.82 2.83 3.84 2.83 3.81 2.84 2.83 3.81 2.84 2.83 3.81 2.84 2.83 3.81 2.84 2.84 2.84 2.84 2.85 3.84 2.84 2.84 2.85 3.84 2.84 2.85 3.84 2.84 2.85 3.84 2.84 2.83 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.98 3.24 1.99 3.24 4.29 5.2
(E.) Cercbrovascular disease Study Study UD Wang et al. 2020a Guan et al. 2020a Guan et al. 2020a Wang et al. 2020b UD NOTE: Weights are from random effects antrojet .00416 C(C) Diabetcs Study Wang et al. 2020b Wang et al. 2020b Wang et al. 2020b Uweng et al. 2020b Wang et al. 2020b Uweng et al. 2020b Uweng et al. 2020b Uweng et al. 2020b Uweng et	181 OR (95% CI) 20.20 (2.34, 174.44 1.26 (0.62, 6.24) 1.26 (0.02, 6.24) 1.26 (0.02, 6.24) 1.26 (0.02, 6.24) 1.26 (0.02, 7.20) 3.57 (1.27, 8.33) 1.28 (0.02, 7.5, 2.19) 3.57 (1.27, 8.33) 1.28 (0.44, 6.04) 2.47 (1.54, 3.97) 1.53 (0.44, 6.04) 2.47 (1.54, 3.97) 2.40 OR (95% CI) 4.50 (2.27, 8.450) 1.90 (0.47, 1.94) 1	% Weight 10,414 10,64 2,18 5,97 1,30 2,201 13,02 2,118 3,95 2,201 100,00 9,02 100,000 % Weight 1,97 2,23 1,05 2,20 9,02 100,000	Budy Divergent al. 2020a Vang et al. 2020a Class et al. 2020a Class et al. 2020a Class et al. 2020a Charge et al. 2020a Class et al. 2020a Charge et al. 2020b Class et al. 2020b Verse et al. 2020b	2ase	OR (95% CI) 5.00 (226, 11.44) 1.80 (2.11.34) 2.00 (1.34, 12.97) 1.50 (2.45, 1.34) 1.50 (2.45, 1.34) 1.	% Weight 2.37 2.62 3.842 2.62 3.842 2.62 3.842 2.62 3.842 2.62 3.842 2.63 3.842 2.63 3.842 2.63 3.842 2.43 3.852 2.43 3.842 2.43 3.842 2.54 3.842 2.54 3.948 2.543 3.02 2.43 1.09 8.11 1.93 3.12 2.55 1.65 3.142 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.842 2.55 3.85 2.55 3.55 3.55 3.55 3.55 3.55 3.55 3.5
(E) Cerciprovascular disease Study Study Uo Wang et al. 2020 Guan et al. 2020 Guan et al. 2020 Wang et al. 2020 Yang et al. 2020 Wang et al. 2020 Overall (i-quared = 28.4%, p = 0.152) NOTE: Weights are from machom effects analysis Out16 Tang et al. 2020 Yang et al. 2020	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 2.65 (0.19, 3.67) 2.63 (0.47, 14.80) 3.87 (1.37, 6.33) 1.26 (0.31, 6.38, 240.26) 3.85 (0.43, 363.49) 1.36 (0.31, 6.38, 240.26) 3.95 (0.33, 363.49) 1.53 (0.07, 52.91) 1.53 (0.07, 52	% Weight 10.64 10.64 10.64 10.64 10.64 10.64 10.64 10.02 11.02 10.02 10.02 % Weight 10.02 % Weight 10.02 100.00 % % Weight 1.51 1.51 1.51 1.52 1.51 1.51 1.52 1.51 1.52 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.54 1.55 1.55 1.55 1.55 1.55 1.55 1.55	Budy Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Maren et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al. 2020a Diversity of al. 2020a Channer et al. 2020a Diversity of al. 2020a Diversity of al.		OR (95% CI) 5.00 (226, 11.44) 1.80 (0.11.32, 220) 1.80 (0.11.32, 220) 1.80 (0.11.32, 220) 1.80 (0.11.32, 220) 1.80 (0.14, 2.20) 1.80 (0.14, 2.20) 1.80 (0.14, 2.20) 1.80 (0.14, 2.20) 1.80 (1.14, 2.20) 1.80 (1.14, 2.20) 1.80 (1.14, 2.20) 1.80 (1.14, 2.20) 1.82 (1.16, 2.87) 1.80 (1.14, 2.20) 1.82 (1.16, 2.87) 1.80 (1.14, 2.20) 1.82 (1.16, 2.87) 1.80 (1.14, 15.23) 1.82 (1.16, 2.87) 1.80 (1.14, 15.23) 1.82 (1.16, 2.87) 1.80 (1.14, 15.23) 1.84 (1.16, 2.87) 1.84 (1.	% Weight 2.37 2.62 3.842 2.62 3.842 2.62 3.842 2.62 3.842 2.63 3.89 2.63 3.84 2.63 3.854 2.63 3.854 2.63 3.652 2.27 3.82 2.28 3.622 2.28 3.622 2.28 3.622 2.28 3.622 2.28 3.622 2.28 3.622 2.28 3.622 2.28 3.622 2.283 3.624 3.19 0.000 0.243 2.284 3.032 1.963 2.283 3.024 4.630 0.044 3.032 2.284 3.032 4.439 1.090 2.254 1.09 3.034 4.630 0.044 3.032 3.046 4.630 0.044 3.044 4.630 0.044 3.044 4.630 3.044 4.630 3.033 3.18 2.274 2.274 2.274 2.274 2.275 3.022 2.275 3.022 2.275 3.022 2.275 3.024 4.643 3.034 2.254 3.024 4.643 3.044 4.630 3.044 4.630 3.318 3.318 3.318 3.044 4.630 3.318 3.318 3.318 3.318 3.044 3.0
(E) Cerebrovascular disease Study ID Wang et al. 2020a Gounn et al. 2020 Wang et al. 2020b Yang et al.	181 OR (95% CI) 20 20 (2 34, 174 44 1.24 (0.62, 5.24) 1.24 (0.62, 5.24) 1.24 (0.62, 7.24) 2.63 (0.47, 14.80) 9.55 (0.38, 240.26) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.35 (0.43, 358) 3.35 (0.43, 353) 1.28 (0.75, 2.19) 1.38 (0.75, 2.19) 1.38 (0.75, 2.19) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.55 (0.07, 32.91)	% Weight 14.14 10.64 2.18 7.33 5.97 2.01 13.02 2.11 13.02 2.11 13.02 2.11 13.02 2.11 13.02 2.11 13.02 2.00 9.02 100.00 9.02 10	Budy Diverget al. 2020a Wang et al. 2020a Diverget al. 2020a Wang et al. 2020a Diverget al. 2020a Damag et al. 2020a Diverget al. 2020a Case et al. 2020a Diverget al. 2020a Damag et al. 2020a Diverget al. 2020a Damag et al. 2020a Diverget al. 2020a Damag et al. 2020a Diverget al. 2020a Diverget al. 2020a Diverget al. 2020a Diverget al. 2020a Diverget al. 2020a Viet al. 2020a Diverget al. 2020a Viet al. 2020a Diverget al. 2020a Diverget al. 2020a Diverget a		OR (95% CI) 5.00 (226, 11.48) 1.60 (51.32) 2.06 (0.33, 167) 1.50 (0.45, 6.03) 1.60 (0.31, 6.07) 2.46 (0.45, 7.10) 2.46 (1.64, 4.20) 1.60 (1.44, 2.14) 4.70 (2.25, 10.44) 1.65 (1.16, 4.21) 1.65 (1.16, 4.21) 1.71 (1.14, 15.85) 1.72 (1.64, 4.20) 1.72 (1.14, 15.85) 1.72 (1.64, 4.21) 1.72 (1.64, 4.21) 1.7	% Weight 2.37 2.62 3.842 2.62 3.842 2.62 3.842 2.62 3.842 2.62 3.84 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 2.62 3.94 1.63 3.04 2.62 2.54 2.62 3.04 2.62 3.04 2.62 3.04 2.62 3.04 2.62 3.04 2.62 3.04 2.62 3.04 3.04 2.62 3.04 3.04 2.62 3.04 3.04 2.62 3.04 3.04 2.62 3.04 3.04 3.04 2.62 3.04 3.04 3.04 2.62 3.04 3.04 3.04 2.62 3.04 3.04 3.04 3.04 3.04 3.04 3.04 3.04
(E) Cerebrovascular disease Study Study Wang et al. 2020a Guann et al. 2020 Wang et al. 2020a Wang et al. 2020b The et al. 2020b Wang et al. 2020b	181 OR (95% CI) 20.20 (2.34, 174 44 1.26 (0.62, 6.24) 1.26 (0.02, 6.24) 1.26 (0.02, 6.24) 0.85 (0.19, 3.87) 2.63 (0.47, 14.80) 3.37 (1.27, 8.33) 1.28 (0.02, 5.24) 3.55 (0.33, 6.24, 200) 3.57 (1.7, 8.33) 1.28 (0.47, 18, 83) 1.58 (0.44, 6.04) 2.57 (1.04, 73.59) 1.58 (0.44, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 1.27 (46, 14.29) 3.57 (1.12, 45, 10.19) 3.67 (1.12, 45, 10.19) 3.76 (1.12, 45, 10.19) 3.89 (0.43, 10.11, 11.44, 5.11) 2.40	% Weight 14.14 2.18 7.33 5.97 2.01 13.02 2.1.18 3.95 7.06 4.23 9.02 100.00 10.00 10.	Budy Jung et al. 2020a Vang et al. 2020a Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Charler et al. 2020 Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Caller et al. 2020 Ver et al. 2020 Caller et al. 2020 Contral (Heyauret = 67.9%, p. = 0.000) NOVertal (Heyauret = 67.9%, p. = 0.000) Ver et al. 2020 Caller et al. 2020 Chan et al. 2020<	**************************************	OR (95% CI) 5.00 (226, 11.48) 1.80 (0.51, 226, 11.48) 1.80 (0.51, 227, 11.48) 1.80 (0.51, 22	% Weight 2.37 2.62 3.842 2.62 3.942 2.62 3.942 2.62 3.942 2.62 3.942 2.62 3.942 2.62 3.942 2.62 3.942 2.62 3.942 2.62 2.62 3.942 2.62 3.942 2.62 3.942 2.62 2.62 2.62 3.942 2.62 3.94 3.943 3.943 3.943 3.943 3.944 1.946 3.942 2.454 1.946 3.943 3.944 3.943 3.944
(E) Cerciprovascular disease Study Study Uo Wang et al. 2020 Guan et al. 2020 Guan et al. 2020 Wang et al. 2020 Yung et al. 2020 Wang et al. 2020 Wang et al. 2020 Wang et al. 2020 Wang et al. 2020 Vang et al. 2020 Vang et al. 2020 Voerall (!equared - 28.4%, p = 0.152) NOTE: Weights are from random effects analysis Loo416 10 Zhang et al. 2020 Yang et al. 2020	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 2.65 (0.19, 3.67) 2.63 (0.47, 14.80) 3.87 (1.37, 6.33) 1.26 (0.31, 6.38, 240.26) 3.87 (1.37, 6.33) 1.26 (0.31, 6.38, 240.26) 3.85 (0.43, 3.63.4) 1.46 (0.31, 6.38) 1.53 (0.07, 3.2.91) 1.63 (0.44, 6.04) 2.47 (1.44, 3.97) 2.40 OR (95% CI) 4.57 (1.46, 1.428) 1.30 (0.47, 3.54) 1.53 (0.07, 3.2.91) 1.53 (0.07, 3.52) 1.53 (0.07, 3.52) 1.54 (0.07, 3.52) 1.55 (0.	% Weight 14.14 14.14 10.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.04 4.23 2.20 9.02 100.00 9.02 100.00 9.02 100.00 % Weight 1.37 1.51 1.51 1.52 1.53 3.95 6.05 8.00 2.53 8.32 3.32 3.32 3.32 3.32 3.32 3.32 3.3	Budy Diversity of al. 2020a Variang et al. 2020a Class et al. 2020a Class et al. 2020a Class et al. 2020a Charles et al. 2020a Class et al. 2020a Variang et al. 2020a Class et al. 2020a Subsymmet et al. 2020a Class et al. 2020a Subsymmet et al. 2020a Class et al. 2020a Class et al. 2020a Class et al. 2020a Class et al. 2020a Class et al. 2020a Variang et al. 2020a Class et al. 2020a		OR (95% CI) 5.00 (226, 11.44) 1.80 (0.11.32, 227) 1.50 (0.45, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.94) 4.04 (274, 5.94) 4.04 (274, 5.94) 4.04 (274, 5.94) 4.04 (274, 5.94) 4.04 (274, 5.94) 4.05 (1.44, 4.26) 4.05 (1.44, 4.26) 4.07 (2.45, 10.94) 4.07 (1.44, 15.287) 1.06 (1.05, 2.77) 4.07 (1.44, 15.287) 1.06 (1.05, 2.77) 4.07 (1.44, 15.287) 1.07 (1.44, 15.37) 1.07 (1.45, 10.457) 1.07 (1.45	% Weight 2.37 2.62 3.84 3.84 3.84 3.85 3.85 3.85 3.85 3.85 3.85 3.85 3.85
Cerciprovascular disease Study Study Wang et al. 2020a Wang et al. 2020b	181 OR (95% CI) 20 20 (2 34, 174 44 196 (0.82, 6.24) 1.24 (0.06, 27.20) 2.65 (0.19, 3.67) 2.63 (0.47, 14.80) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.35 (0.43, 354 3.35 (1.04, 7.56) 3.35 (1.04, 7.56) 3.35 (1.04, 7.56) 3.35 (1.04, 7.56) 3.36 (0.43, 3.55) 3.46 (0.31, 6.83) 1.58 (0.07, 22.91) 1.63 (0.44, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 4.57 (1.44, 7.56) 3.17 (1.44, 5.18) 3.17 (1.44, 5.18) 3.17 (1.45, 5.18) 3.18 (1.45, 5	% Weight 14.14 14.14 10.64 2.18 7.33 5.97 2.01 13.02 2.1.18 3.95 7.04 4.23 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 10.20 9.02 10.00 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.20 9.02 10.00 9.02 10.20 9.02 10.00 9.02 10.00 9.02 10.20 9.02 10.00 9.02 10.00 9.02 10.00 9.02 10.00 1	Budy Jung et al. 2020a Wang et al. 2020a Jung et al. 2020a Wang et al. 2020a Jung et al. 2020a Zhang et al. 2020a Jung et al. 2020a Ywn et al. 2020a Jung et al. 2020a Ywn et al. 2020a Jung et al. 2020a Ywn et al. 2020a Jung et al. 2020a Jung et al. 2020a Jung et al. 2020a		OR (95% CI) 5.00 (226, 11.48) 1.60 (0.31, 3.67) 1.60 (0.31, 3.67) 1.60 (0.31, 3.67) 1.60 (0.31, 3.67) 1.60 (0.31, 3.67) 1.60 (0.44, 6.03) 1.60 (0.44, 6.03) 1.60 (0.44, 6.03) 1.60 (0.44, 6.03) 1.60 (0.44, 6.03) 1.60 (0.45, 2.14) 1.70 (0.46, 6.14) 1.70 (0.46, 1.41) 1.70 (0.46, 4.48) 1.77 (0.46, 1.41) 1.70 (0.46, 4.48) 1.70 (0.46, 4.48) 1.70 (0.46, 4.48) 1.70 (0.46, 4.48) 1.70 (0.46, 4.48) 1.70 (0.46, 4.48) 1.70 (0.47, 1.13) 1.80 (0.44, 1.30) 1.80 (0.34, 1.20) 2.42 (0.03, 2.80) 1.44 (1.35, 6.03) 2.44 (0.15, 3.95) 2.44 (0.15, 3.95) 2.45 (0.47, 1.48) 3.90 (0.25, 5.71) 1.44 (0.35, 6.03) 2.45 (0.47, 1.48) 3.90 (0.27, 2.11, 1.48) 3.	% Weight 2.37 3.42 3.64 3.42 3.64 3.62 4.64 3.62 4.64 3.63 3.63 4.64 2.747 4.65 3.63 4.64 2.03 3.64 2.03 3.64 2.03 3.64 2.03 3.64 2.03 3.64 2.03 3.64 4.03 3.65 4.64 2.03 3.64 4.65 3.53 4.64 4.65 3.53 4.64 4.65 4.65 4.65 4.65 4.65 4.65 4.65
Cercbrovascular disease Study Study Uo Wang et al. 2020a Guann et al. 2020 Wang et al. 2020b Wang et al. 2021b Doverall (lequaret = 2.8.4%, p = 0.152) NOTE: Weights are from random effects analysis Io Wang et al. 2020b	181 OR (95% CI) 20.20 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.85 (0.19, 3.87) 2.85 (0.19, 3.87) 2.85 (0.13, 8.240.26) 3.87 (1.27, 8.83) 1.28 (0.05, 5.26) 3.85 (0.43, 3.55, 56.70) 8.75 (1.04, 75.59) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.53 (0.46, 6.04) 2.47 (1.54, 3.87) 240 OR (95% CI) 2.26 (0.27, 3.48) 3.95 (0.43, 3.51, 10.28) 3.95 (0.43, 1.51, 10.28) 3.95 (0.43, 1.51, 10.28) 2.40 (0.27, 3.48) 2.27 (0.76, 6.80) 1.28 (0.07, 1.16, 1.128) 3.95 (0.43, 1.16, 1.128) 3.95 (0.43, 1.16, 1.128) 2.28 (0.08, 1.16, 1.128) 3.96 (1.13, 5.11, 10.28) 3.96 (1.13, 5.11, 10.28) 3.96 (1.13, 1.128) 3.96 (1.13, 1.128) 3.96 (1.13, 1.128) 3.96 (1.13, 1.128) 3.96 (1.13, 1.128)	% Weight 14.14 110.64 2.18 7.33 5.97 2.01 13.02 21.18 3.95 7.04 9.02 1100.00 9.02 9.02 9.02 9.02 1100.00 9.02 9.02 1100.00 9.02 9.02 9.02 1100.00 9.02 9.02 9.02 1100.00 9.02 9.02 11.28 4.23 2.29 0.04 2.23 8.29 4.23 1.28 4.23 1.28 4.23 1.28 4.23 1.28 4.23 1.28 4.23 1.28 4.23 2.29 1.18 2.29 0.04 2.29 2.29 1.18 3.29 5.20 1.19 2.29 2.29 1.18 2.29 2.29 2.29 2.29 2.29 2.29 2.29 2.2	Budy Wang et al. 2020a Vang et al. 2020a Caller et al. 2020a Caller et al. 2020a Caller et al. 2020a Ver et al. 2020a		OR (95% CI) 5.00 (226, 11.48) 1.80 (91, 32) 2.00 (034, 1.87) 1.50 (94, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.05 (144, 4.23) 4.05 (144, 4.23) 4.05 (144, 4.23) 4.05 (145, 247) 4.05 (145, 145) 3.06 (147, 147) 3.06 (147, 147) 3.00 (10.25, 571) 1.04 (10.35, 163) 3.02 (10.02, 571) 1.04 (10.35, 163) 3.02 (10.02, 571) 1.04 (10.25, 543) 3.05 (127, 121, 123) 3.05 (120, 123	% Weight 2.37 3.84 3.84 3.84 3.84 3.84 3.84 3.84 3.84
CE: Occupation Constraint Study June Study June Wang et al. 2020a June Guan et al. 2020a June Hong et al. 2020a June Wang et al. 2020b June Yang et al. 2020b June Wang et al. 2020b June Yang et al. 2020b June Wang et al. 2020b June Yang et al. 2020b June	181 OR (95% CI) 20.20 (2.34, 174 44 1.96 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.18, 24, 02) 0.85 (0.18, 38.7) 2.63 (0.47, 14.80) > 9.55 (0.38, 240.25) 3.37 (1.27, 8.33) 1.28 (0.42, 5.3, 56.70) 3.55 (0.43, 24.25) 3.56 (0.43, 6.38, 240.25) 1.58 (0.44, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 4.57 (1.04, 7.3.59) 3.77 (1.24, 5.18) 3.70 (1.27, 3.59) 3.71 (1.24, 5.16) 2.40 OR (95% CI) 4.57 (1.04, 7.3.59) 3.77 (1.44, 1.23) 3.75 (1.94, 7.3.59) 3.75 (1.94, 7.3.59) 3.75 (1.94, 7.16) 3.87 (1.94, 5.16) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93) 3.98 (0.65, 1.93)	% Weight 14.14 10.64 2.18 5.97 2.01 13.02 21.185 3.02 100.00 19.02 100.00 % Weight 19.02 100.00 19.02 100.00 19.02 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.23 4.55 3.00 1.22 1.22 4.55 3.00 1.22 1.22 4.55 3.00 2.23 1.00 1.22 1.22 4.55 3.00 2.23 4.55 3.00 2.23 1.22 4.55 3.00 2.23 1.22 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.00 2.23 4.55 3.50 5.57 4.55 3.50 5.57 5.57 5.57 5.57 5.57 5.57 5.57 5	Budy D Vang et al. 2020a Cause		OR (95% CI) 5.00 (226, 11.44) 1.00 (21, 23, 24) 2.00 (134, 126) 1.50 (24, 5, 25) 4.04 (274, 5, 26) 4.04 (274, 5, 26) 4.04 (274, 5, 26) 4.04 (274, 5, 26) 4.05 (274, 5, 26) 4.00 (274, 5, 27) 4.00 (275, 571) 4.04 (272, 274) 4.04 (275, 274) 4.04 (275, 274) 4.04 (275, 274) 4.04 (275, 274) 4.04 (275, 274) 4.04 (275, 274) 4.05 (274, 274) 4.05 (% weight 2.37 2.47 3.42 3.42 3.42 3.42 3.42 3.42 3.42 4.47 2.49 3.04 4.43 1.139 4.131 3.16 4.131 4.72 6.03 1.13,147 2.47 2
(E) Cerciprovascular disease Study Study Uo Wang et al. 2020a Gaunet al. 2020a Wang et al. 2020b Uot et al. 2020	181 OR (95% CI) 20 20 (2 34, 174 44 196 (0.62, 6.24) 1.24 (0.06, 27.20) 2.65 (0.19, 3.67) 2.63 (0.47, 14.80) 3.37 (1.27, 6.93) 1.26 (0.75, 2.19) 3.37 (1.27, 6.93) 1.26 (0.75, 2.19) 3.35 (0.43, 356, 356, 70) 3.35 (0.43, 355, 357, 70) 4.56 (0.31, 6.84) 2.47 (1.44, 3.57) CR (95% CI) OR (95% CI) CR (95% CI) 0.45 (0.47, 3.59) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.54 (0.07, 32.91) 1.55 (0.07, 32.91) 2.55	% Weight 14.14 10.64 2.18 5.97 2.01 13.02 2.1.18 5.97 7.06 4.23 2.20 100.000 *% Weight 1.97 1.05 2.20 1.05 2.20 1.00 2.20 2	Budy Wang et al. 2020a Amag e		OR (95% CI) 5.00 (226, 11.48) 1.80 (9.13, 201 1.80 (9.13, 201 1.80 (9.13, 201 1.80 (9.13, 201 1.80 (9.13, 201 1.80 (9.14, 201 1.80 (9.	% weight 2.37 2.37 2.644 1.422 2.37 2.644 1.425 2.644 1.425 2.644 1.425 2.647 2.262 2.47 3.17 2.262 2.47 3.17 2.262 2.47 3.19 3.27 2.264 3.19 3.27 2.265 3.31 1.99 3.054 2.265 3.31 1.99 3.054 1.060 3.18 1.62 2.442 1.148 6.30 1.162 1.162 1.162 3.034 1.67 1.67
(E) Cercbrovascular disease Study Study Uo Wang et al. 2020a Guann et al. 2020 Hong et al. 2020b Yang et al. 2020b	181 OR (95% CI) 20 20 (2 34, 174 44 196 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 14.80) 9.955 (0.38, 240.26) 3.37 (1.27, 6.83) 1.28 (0.75, 2.19) 3.35 (0.43, 355, 3.57) 1.53 (0.07, 32.91) 1.53 (0.44, 6.44) 2.47 (1.54, 3.87) 2.40 OR (85% CI) OR (85% CI) 0.75 (1.44, 1.428) 1.15 (0.54, 1.45) 0.75 (1.44, 1.428) 1.15 (0.54, 1.45) 0.75 (1.44, 1.428) 1.15 (0.54, 1.45) 0.75 (1.45, 1.428) 0.75 (1.45, 1.428) 1.53 (0.64, 6.44) 2.47 (1.54, 3.87) 2.40 OR (85% CI) 0.75 (0.54, 1.54) 0.75 (0.54, 1.54) 0.7	% Weight 10.64 2.18 5.97 7.06 4.23 3.95 7.06 4.23 9.02 100.00 0.05 10.05 0.05 2.00 10.05 0.05 2.00 10.05 0.05 0.05 0.05 0.05 0.05 0.05	Budy D Vang et al. 2020a Dama et al. 2020a Case		OR (95% CI) 5.00 (226, 11.48) 1.80 (0.51, 226, 11.48) 1.80 (0.51, 227, 11.48) 1.80 (0.51, 228) 2.24 (0.01, 2.78) 2.24 (0.01, 3.78) 1.20 (0.02, 5.71) 1.44 (0.33, 5.63) 1.24 (0.03, 1.78) 1.26 (0.67, 2.45) 1.26	% Weight 1237 2372 2374 2484 3142 1420 2373 2484 3142 2484 2484 2484 2484 2484 2484 2484 2
(E) Corrovascular disease Study Study Unit Wang et al. 2020a Guan et al. 2020a Guan et al. 2020a Wang et al. 2020b User al. 2020b Wang et al. 2020b Uwang et al. 2021b Dott6 COD Uwang et al. 2020b Wang et al. 2020b Uwang et al. 2020b<	181 OR (95% CI) 20.20 (2.34, 174 44 1.26 (0.62, 6.24) 1.26 (0.62, 6.24) 1.26 (0.62, 6.24) 1.26 (0.62, 6.24) 2.63 (0.47, 14.80) 3.37 (1.27, 8.33) 1.28 (0.62, 5.24) 1.28 (0.63, 242.02) 3.37 (1.27, 8.33) 1.28 (0.75, 2.16) 3.55 (0.43, 5.65, 70) 8.75 (1.04, 73.59) 1.53 (0.44, 6.04) 2.47 (1.54, 3.97) 240 OR (95% CI) 4.57 (1.04, 73.59) 3.17 (1.27, 45.142) 3.26 (0.43, 5.65, 70) 3.27 (1.27, 45.142) 3.38 (0.64, 5.163, 2.75, 1.163) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.47 (1.54, 5.16, 70) 3.46 (3.51, 10.86) 3.46 (3.51, 10.86)	% Weight 10.64 2.18 5.97 2.01 13.02 2.1.18 3.02 2.01 13.02 2.01 13.02 2.01 100.00 1.97 7.06 4.23 100.00 1.97 7.04 4.23 100.00 1.97 1.02 1.02 1.02 2.09 100.00 1.97 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.01 1.02 2.00 1.02 2.00 1.00 0.02 0.02	Budy Wang et al. 2020a Vang et al. 2020a Caller et al. 2020a Caller et al. 2020a Caller et al. 2020a Chang et al. 2020a Caller et al. 2020a Vive et al. 2020a Caller et al. 2020a Vive et al. 2020a Caller et al. 2020a Vive et al. 2020a Caller et al. 2020a Chang et al. 2020a		OR (95% CI) 5.00 (226, 11.48) 1.80 (0.1) (2.4) 2.00 (0.3), 1.20 1.50 (0.4) (2.4) 2.00 (0.3), 1.20 1.50 (0.4) (2.4) 2.00 (0.3), 1.20 2.48 (0.68 (7.10) 2.48 (1.68 (7.10) 2.44 (1.13 (7.10) 2.45 (% Weight 237 237 242 244 244 245 245 245 245 245 245 247 228 247 247 228 247 247 228 247 247 248 247 247 248 247 247 248 247 247 247 247 247 247 247 247 247 247
Observation of the second sec	181 OR (95% CI) 2020 (2.34, 174.44 1.96 (0.62, 6.24) 1.24 (0.06, 27.20) 2.65 (0.19, 3.67) 2.63 (0.47, 14.80) 3.87 (1.37, 6.33) 1.26 (0.75, 2.19) 3.85 (0.43, 363.40 3.85 (0.43, 363.40) 3.85 (0.43, 363.40) 1.36 (0.31, 6.38) 3.85 (0.43, 363.40) 1.36 (0.31, 6.38) 3.75 (1.04, 73.59) 3.75 (1.04,	% Weight 10.64 2.18 3.95 7.06 4.23 100.00 9.02 100.00 9.02 100.00 9.02 2.29 100.00 9.02 2.29 100.00 9.02 2.29 100.00 9.02 2.29 100.00 9.02 2.29 100.00 9.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 1.02 2.29 2.29 2.29 2.29 2.29 2.29 2.29 2	Budy Divergent al. 2020a Vange et al. 2020a Classe et al. 2020a Classe et al. 2020a Classe et al. 2020a Charles et al. 2020a Classe et al. 2020a Vere et al. 2020a Clase et al. 2020a <td< td=""><td></td><td>OR (95% CI) 5.00 (226, 11, 48) 1.80 (0, 13, 26, 11, 48) 1.80 (0, 13, 16, 11, 14) 1.80 (0, 14, 26, 12) 1.80 (0, 14, 16, 16) 1.80 (0, 16, 16, 16) 1.80 (0, 16, 16, 16) 1.80 (0, 17, 14, 12) 1.80 (0, 17, 14) 1.80 (0</td><td>% weight 2.37 2.644 2.37 2.644 1.422 2.634 1.422 2.634 1.425 2.635 2.647 1.445 2.635 2.647 1.445 2.635 2.647 1.445 2.635 2.647 2.622 2.627 2.622 2.627 2.622 2.637 2.642 2.635 2.644 2.635 2.644 2.635 2.644 2.635 2.644 2.635 2.644 2.645 1.995 2.635 2.644 2.645 1.995 2.635 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.644 2.645 1.995 2.644 2.644 2.645 1.995 2.644 2.644 2.644 2.645 1.995 2.644 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.645 2.645 2.645 2.645 2.645 2.644 2.645 2.645 2.644 2.6455 2.645 2.64555 2.64555 2.64555555555555555555555555555555555555</td></td<>		OR (95% CI) 5.00 (226, 11, 48) 1.80 (0, 13, 26, 11, 48) 1.80 (0, 13, 16, 11, 14) 1.80 (0, 14, 26, 12) 1.80 (0, 14, 16, 16) 1.80 (0, 16, 16, 16) 1.80 (0, 16, 16, 16) 1.80 (0, 17, 14, 12) 1.80 (0, 17, 14) 1.80 (0	% weight 2.37 2.644 2.37 2.644 1.422 2.634 1.422 2.634 1.425 2.635 2.647 1.445 2.635 2.647 1.445 2.635 2.647 1.445 2.635 2.647 2.622 2.627 2.622 2.627 2.622 2.637 2.642 2.635 2.644 2.635 2.644 2.635 2.644 2.635 2.644 2.635 2.644 2.645 1.995 2.635 2.644 2.645 1.995 2.635 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.645 1.995 2.644 2.644 2.645 1.995 2.644 2.644 2.645 1.995 2.644 2.644 2.644 2.645 1.995 2.644 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.644 2.645 2.645 2.645 2.645 2.645 2.645 2.644 2.645 2.645 2.644 2.6455 2.645 2.64555 2.64555 2.64555555555555555555555555555555555555
(E) Cerciprovascular disease Study Study Io Wang et al. 2020 Jourg et al. 2021 Jourg et al. 2021 Jourg et al. 2021 Jourg et al. 2020 Jourg et al. 2020 </td <td>181 OR (95% CI) 20 20 (2 34, 174 44 196 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 14.80) 9.85 (0.33, 282 (0.47, 14.80) 9.85 (0.33, 282 (0.47, 14.80) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.35 (0.43, 353 (0.47, 14.80) 3.35 (0.43, 355 (0.47, 14.80) 3.35 (0.44, 5.55 (0.47, 35.80) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.54 (0.07, 32.91) 1.54 (0.07, 32.91) 1.55 (0.07, 32.9</td> <td>% Weight 10.64 2.18 5.97 7.06 4.23 3.95 7.06 4.23 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 10.04 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 2.28 10.04 2.28 2.28 2.28 2.28 2.28 2.28 2.28 2.2</td> <td>Budy Jung et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Cas et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Wang et al. 2020a Zhang et al</td> <td></td> <td>OR (95% CI) 5.00 (226, 11.48) 1.69 (0.51, 264) 1.69 (0.54, 264) 1.69 (0.54, 214) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.75 (1.05, 242) 1.75 (1.05, 242)</td> <td>% Weight 2.37 2.84 3.42 3.42 3.42 3.42 3.43 3.42 3.43 3.43</td>	181 OR (95% CI) 20 20 (2 34, 174 44 196 (0.82, 6.24) 1.24 (0.06, 27.20) 0.85 (0.19, 3.87) 2.83 (0.47, 14.80) 9.85 (0.33, 282 (0.47, 14.80) 9.85 (0.33, 282 (0.47, 14.80) 3.37 (1.27, 6.93) 1.28 (0.75, 2.19) 3.35 (0.43, 353 (0.47, 14.80) 3.35 (0.43, 355 (0.47, 14.80) 3.35 (0.44, 5.55 (0.47, 35.80) 1.53 (0.07, 32.91) 1.53 (0.07, 32.91) 1.54 (0.07, 32.91) 1.54 (0.07, 32.91) 1.55 (0.07, 32.9	% Weight 10.64 2.18 5.97 7.06 4.23 3.95 7.06 4.23 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 10.04 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 10.04 2.28 2.28 10.04 2.28 2.28 2.28 2.28 2.28 2.28 2.28 2.2	Budy Jung et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Cas et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Zhang et al. 2020a Wang et al. 2020a Zhang et al		OR (95% CI) 5.00 (226, 11.48) 1.69 (0.51, 264) 1.69 (0.54, 264) 1.69 (0.54, 214) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.65 (1.64, 2420) 1.75 (1.05, 242) 1.75 (1.05, 242)	% Weight 2.37 2.84 3.42 3.42 3.42 3.42 3.43 3.42 3.43 3.43
(E) Cerebrovascular disease Sludy Wang et al. 2020a Guan et al. 2020 Hong et al. 2020 Hong et al. 2020 Yang et al. 2020 Yang et al. 2020 Wang et al.	181 OR (95% CI) 20.20 (2.34, 174.44 1.24 (0.06, 27.20) 0.85 (0.19, 3.67) 2.83 (0.26, 2.44) 1.24 (0.06, 27.20) 2.85 (0.19, 3.67) 2.83 (0.47, 14.80) 3.95 (0.43, 55, 56.70) 3.95 (0.43, 55, 56.70) 8.75 (1.04, 73.59) 1.53 (0.47, 14.80) 1.53 (0.47, 14.50) 8.75 (1.04, 73.59) 1.53 (0.46, 6.34) 2.47 (1.54, 3.87) 240 OR (95% CI) 4.57 (1.46, 14.24) 3.96 (0.43, 55.80) 3.97 (1.27, 6.83) 1.53 (0.40, 73.291) 3.98 (0.45, 15.32) 2.440 OR (95% CI) 4.57 (1.46, 14.28) 3.98 (0.64, 71.59) 3.98 (0.65, 16.32) 2.28 (0.06, 11.86) 3.98 (0.64, 71.37) 3.99 (0.64, 72.71) 3.90 (0.47, 1.59) 3.90 (0.47, 1.59) 3.90 (0.47, 1.59) 3.90 (0.47, 1.59) 3.90 (0.47, 1.59) 3.90 (0.47, 1.59) <	% Weight 10.64 2.18 5.97 7.06 4.23 11.0.64 2.20 10.0.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 100.00 9.02 1.05 2.05 2.05 2.05 2.05 2.05 2.05 2.05 2	Budy Wang et al. 2020a Jamag et al. 2020a Jamag et al. 2020a Call et al. 2020a Jamag et al. 2020a Jamag et al. 2020a Jamag et al. 2020a Ver et al. 2020a Jamag et al. 2020a Jamag et al. 2020a Jam		OR (95% CI) 5.00 (226, 11.48) 1.80 (91, 32) 2.00 (034, 1.87) 1.50 (94, 5.03) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.04 (274, 5.93) 4.05 (144, 214) 4.70 (144, 5.83) 4.04 (145, 5.04) 4.70 (144, 5.83) 5.26 (245, 10.80) 5.26 (247, 10.80) 5.24 (203, 2.88) 5.24 (203, 2.88) 5.27 (247, 10.80) 5.26 (247, 10.80) 5.27 (247, 11.80) 5.27 (247, 11.80) 5.26 (247, 11.80) 5.27 (247, 11.80) 5.26 (247, 11.80) 5.27 (247, 12.80) 5.26 (247, 14.80) 5.27 (247, 12.80) 5.27 (14.80) 5.27 (10.97, 3.22) 5.27 (10.74, 6.22) 5.27 (10.74, 6.22) 5.27 (10.74, 6.22) 5.27	% Weight 237 2484 3142 3142 3142 3142 3142 3142 3145 3142 3145 3145 3145 3145 3145 3145 3145 3145

Fig 3. Meta-analysis of the association between comorbidities and severe COVID-19 disease. (A-H) Forest plots of the association between (A) Chronic kidney disease, (B) Chronic obstructive pulmonary disease, (C) Coronary heart disease, (D) Malignancy, (E) Cerebrovascular disease, (F) Hypertension, (G) Diabetes, (H) Chronic liver disease and severe COVID-19 disease.

https://doi.org/10.1371/journal.pone.0250602.g003

were the main obstacles to recovery. Therefore, more attention should be paid to those obese elderly males with a history of smoking, and the above comorbidities or complications since they are more likely to develop the severe from of the disease. Although four previous studies [52, 53, 55, 57–59] have reported some risk factors for severe COVID-19, our analysis involved and reported on new factors obesity and chronic liver disease. In this study, the quality of evidence was higher since all the included studies were cohort studies rather than case-control studies, and we have included 41 eligible studies that were published from February,2020 to March, 2021, spanning a period of seven months.

Some studies have suggested that innate immunity and some factors associated with sex chromosomes may lead to the differences in susceptibility and inflammation between females and males. For instance, the X chromosome in the female has encoded some immune regulatory genes which caused lower viral load levels. TLR7, a Toll-like kind of receptor, which is higher in females than males, could enhance immune responses and boost the resistance to COVID-19 [60]. Besides, the circulating concentration of ACE2 (a functional cellular receptor of SARS-CoV-2) is higher in males than females, which could increase the susceptibility to SARS-CoV-2 [61]. Males also smoked at a higher rate than females [62] and that could result in a more vulnerable respiratory system. Therefore, it seems reasonable that women have been found to be more resistant to COVID-19. As for smoking, it suppresses the antiviral mechanisms and alters some cytokine patterns which play a role in the innate mucosal immunity [63]; the viral replication and the severity of COVID-19 would increase to some extent as a result. One study shows that smoking can also enhance the expression of ACE2 [64] and this would raise the susceptibility. With regard to age, it was evident that elderly people had a higher prevalence of comorbidities like diabetes [65] and complications like shock [66], but the OR was still significant when controlling for the above confounding factors. The natural decrease in functional reserve brought about by the physiological aging process could reduce elders' capability to resist infections like COVID-19. Based on the analysis of an increasing number of studies reporting details of BMI, we considered obesity as a risk factor. Obesity could cause more endothelial dysfunction [67] and weaken the immunocompetent cells especially their cytotoxic cell responses [68]. The high level of ACE2 receptor expression in adipocytes may turn the adipose tissue into a viral carrier which could spread SARS-CoV-2 to other organs.

We also found some comorbidities were potentially high-risk factors for severe disease and this is consistent with other recent studies [53, 55, 57–59]. For example, as a chronic respiratory illness, COPD has already led to airflow blockage and so raises the risk of respiratory complications like ARDS. Psychologically, when patients with COPD get COVID-19, they seem to easily become very afraid and anxious [69]. Negative feelings may drive misbehavior and go against recovery, so psychological support is considered important. Though the degree varied, a large number of COVID-19 patients had hypoxaemia which may cause injury or apoptosis of cardiomyocytes [70]. As a result, patients with coronary heart disease were more likely to suffer from severer conditions like heart failure which can easily lead to death. For patients with hypertension, some kinds of blood pressure medications can enhance the expression of ACE2 and leave patients more susceptible to COVID-19 symptoms [71, 72]. However some other studies have shown that ACE2 plays an anti-inflammatory role in RAS and protect patients from ARDS [73, 74]. Therefore, the incidence of COVID-19 was lower but the severity was

Study	9	%
ID	OR (95% CI)	Weight
Wang et al. 2020a	30.49 (9.94, 93.54)	14.92
Guan et al. 2020	16.88 (8.01, 35.61)	19.21
Wan et al. 2020	94.00 (11.91, 741.62)	7.61
Hong et al. 2020	395.18 (20.64, 7564.59)	4.41
Chen et al. 2020 -	7.24 (0.29, 181.18)	3.81
Hu et al. 2020	14.76 (1.90, 114.93)	7.68
Wang et al. 2020b	404.55 (23.76, 6887.02)	4.71
Yang et al. 2020	20.83 (6.74, 64.37)	14.84
Suleyman et al. 2020	83.12 (35.83, 192.82)	18.09
Xiong et al. 2020	71.03 (4.17, 1210.44)	4.71
Overall (I-squared = 48.7%, p = 0.041)	39.59 (19.99, 78.41)	100.00
NOTE: Weights are from random effects analysis		
.00013	1 7565	

(A) Acute respiratory distress syndrome

(B) Shock

Study			%
ID		OR (95% CI)	Weight
Wang et al. 2020a		44.44 (5.48, 360.52)	8.98
Guan et al. 2020		62.60 (8.03, 488.22)	9.24
Wan et al. 2020 -		7.25 (0.29, 181.90)	4.39
Hong et al. 2020		→ 361.00 (18.02, 7233.8	1) 4.98
Chen et al. 2020		6.73 (3.07, 14.76)	26.16
Hu et al. 2020		14.63 (5.09, 42.06)	20.86
Wang et al. 2020b		15.54 (0.62, 387.62)	4.40
Yang et al. 2020		48.93 (2.67, 895.47)	5.25
Du et al. 2020		35.79 (1.80, 713.39)	5.00
Xiong et al. 2020		51.38 (3.00, 880.93)	5.46
Zhang et al. 2021b		34.71 (1.92, 628.72)	5.28
Overall (I-squared = 27.4%, p = 0.183)	\diamond	21.50 (10.49, 44.06)	100.00
NOTE: Weights are from random effects and	alysis		
.00014	1 7	/234	

(C) Acute kidney injury

Study			%
ID		OR (95% CI)	Weight
	1		
Wang et al. 2020a		4.55 (0.73, 28.39)	9.92
Guan et al. 2020		27.44 (3.19, 236.36)	7.92
Wan et al. 2020 -	<u>+</u>	0.58 (0.06, 5.39)	7.56
Hong et al. 2020		- 134.40 (13.94, 1295.98)	7.35
Zhao et al. 2020		26.53 (1.41, 497.65)	4.89
Hu et al. 2020		9.38 (2.11, 41.70)	12.74
Yang et al. 2020		10.20 (1.02, 101.68)	7.19
Suleyman et al. 2020	-	5.72 (3.59, 9.10)	25.84
Xiong et al. 2020 —		8.20 (0.41, 162.41)	4.74
Zhang et al. 2021b		11.07 (2.26, 54.19)	11.86
Overall (I-squared = 40.7%, p = 0.086)	\diamond	8.84 (4.34, 18.00)	100.00
NOTE: Weights are from random effects analysis			
.00077	1 1	296	

Fig 4. Meta-analysis of the association between complications and severe COVID-19 disease. (A-C) Forest plots of the association between (A) Acute respiratory distress syndrome (ARDS), (B) Shock, (C) Acute kidney injury (AKI) and severe COVID-19 disease.

https://doi.org/10.1371/journal.pone.0250602.g004

higher in patients with hypertension. Additionally, prolonged hypertension damages the vascular structure leaving the patients susceptible to serious infections. In terms of diabetes, this could compromise and weaken patients' immune system thus worsening their conditions [75]. The dysfunctional pro-inflammatory cytokine responses due to diabetes could also increase the severity of COVID-19 [7]. Whether malignancy does affect the state of illness or lead to a poor prognosis is still controversial. Though our analysis showed there was a potential relationship between malignancy and severe condition, some articles had conflicting outcomes, and a few articles have even suggested that some patients with cancer may have better clinical outcomes since the possible emergence of cytokine storm was dampened because of their compromised immune systems [76, 77]. In addition to the above results, we have also found chronic renal disease (OR = 2.97, 95% CI: 1.63–5.41) was a potential risk factor for severe COVID-19, although a previous analysis had showed that it was not significantly associated with severe conditions [52]. It is likely that patients with CKD suffer from dysregulation of the immune system [78], which possibly contributed to the increase in severity. A study with similar results to ours has also reported a potential link between chronic liver disease and severe COVID-19 [79]. The hepatic insufficiency of COVID-19 patients could be worsened by potentially hepatotoxic drugs such as remdesivir, lopinavir and ritonavir used to treat the disease, causing more severe conditions [80]. More analyses need to be done in order to provide sufficient information and draw accurate conclusions about the controversial results above.

According to our analysis, ARDS, shock and AKI were the three major complications playing a role in severe conditions. Due to impaired gas exchange and serious inflammation in the alveolar space, patients with ARDS had significant need of ventilation [81]. Some studies [82, 83] suggested tissue plasminogen activator (tPA) may be useful in saving such patients' lives in the face of lack of mechanic ventilation in some areas. AKI is prevalent among severe patients and can be fatal especially when patients required renal replacement therapy [84]. Similarly, shocked patients can die without timely treatment resulting from the lack of effective circulating blood volume. Therefore, it is essential to prevent the occurrence of the above complications and give prompt first aid treatment when such complications occur.

Table 4. Population attributable risks of risk factors.						
Risk factor	Prevalence	OR	PAR			
Smoking history	0.1351	1.40	3.9%			
Obesity	0.1517	1.89	7.1%			
Hypertension	0.1926	2.42	11.3%			
Diabetes	0.1121	2.40	6.5%			
Coronary heart disease	0.0682	2.87	4.4%			
Cerebrovascular disease	0.0299	2.47	1.8%			
Chronic obstructive pulmonary disease	0.0227	2.88	1.5%			
Chronic liver disease	0.0278	1.51	0.9%			
Chronic kidney disease	0.0155	2.97	1.0%			
Malignancy	0.0256	2.60	1.6%			
Shock	0.0579	21.50	5.5%			
Acute respiratory distress syndrome	0.1033	39.59	10.7%			
Acute kidney injury	0.0838	8.84	7.4%			

	Table 4.	Population	attributable risk	cs of risk factor
--	----------	------------	-------------------	-------------------

https://doi.org/10.1371/journal.pone.0250602.t004

	Hubei Province				Outside Hubei Province			
	N	OR (95%CI)	I ²	Р	N	OR (95%CI)	I ²	Р
COPD	8	2.78(1.53,5.06)	25.7%	0.22	17	2.67(1.53,4.68)	58.9%	0.001
CKD	6	3.82(1.44,8.11)	13.5%	0.33	10	3.64(1.55,8.58)	69.1%	0.001
ARDS	5	25.25(12.32,51.74)	0.0%	0.80	6	61.22(19.03,196.94)	67.8%	0.008
AKI	5	8.65(3.42,21.85)	0.0%	0.90	5	9.77(2.65,36.01)	71.1%	0.08

Table 5. Subgroup analysis according to study location.

https://doi.org/10.1371/journal.pone.0250602.t005

We believe the PAFs we calculated are meaningful for public health, because the risk of severe cases is likely to decrease in the wake of reduction in the prevalence of certain conditions. In our analysis, the top risk factor was hypertension with the score of 11.3%, indicating that though the OR of hypertension was not relatively high among all the factors, it did play a more important role than we had thought. The PAFs of ARDS (10.7%) and AKI (7.4%) were also high which showed that they possibly make a considerable contribution to the severity of COVID-19, but there are no specific clinical guidelines to prevent them. Therefore, more attention should be given to some other factors like obesity (7.1%) and diabetes (6.5%) since they can to some extent be prevented through practical guidelines [85] and public health campaigns. The other factors ranged from 0.9% to 5.5% and half of them were around 1.0%, suggesting that they exert less effects on the severity of COVID-19.

We should acknowledge that there are some limitations which may affect the accuracy of the outcomes and should be considered. First, some studies did not explicitly show their criteria for severe patients and non-severe patients, meaning the actual severity of patients with these two outcomes may not be consistent with those studies. Second, detecting significant heterogeneity in some analyses, we chose to use a random effects model to process data but did not identify the clear sources of heterogeneity through subgroup analyses. Third, the



https://doi.org/10.1371/journal.pone.0250602.g005

majority of the patients came from China, so they may not be representative of all patients across the world and so results should be carefully evaluated and accepted cautiously. The conclusion can be updated when more studies from outside China are published. Forth, we have tried to include studies from different cites but some articles may still include duplicated cases since they seldom mentioned the detailed composition of patient groups.

5 Conclusion

In summary, patients with COVID-19 who have the following characteristics: male gender, advanced age, a history of smoking, obesity, hypertension, diabetes, malignancy, coronary heart disease, hypertension, COPD, CKD and chronic liver disease, were more likely to develop the severe form of the disease. The emergence of complications like shock, ARDS, AKI generally increased the risk of the disease developing into the severe condition.

Supporting information

S1 Checklist. PRISMA 2009 checklist. (DOC)

S1 Fig. Funnel plot of (A) sex, (B) smoking history, (C)age, (D) BMI, (E) Chronic kidney disease, (F) Chronic obstructive pulmonary disease, (G) Coronary heart disease, (H) Malignancy, (I) Cerebrovascular disease, (J) Hypertension, (K)Diabetes, (L) Chronic liver disease, (M) Acute respiratory distress syndrome (ARDS), (N) Shock, (O) Acute kidney injury (AKI) and severe COVID-19 disease for the assessment of publication bias. (TIF)

S1 Table. Search strategy in four electronic databases. (DOCX)

Acknowledgments

We sincerely thank Associate Professor Yongzhen Yi for her professional opinion on statistical methods.

Author Contributions

Writing - original draft: Xinyang Li, Xianrui Zhong.

Writing - review & editing: Yongbo Wang, Xiantao Zeng, Ting Luo, Qing Liu.

References

- World Health Organization. Coronavirus disease (COVID-19) outbreak, https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/interactive-timeline#! (accessed 10 August 2020).
- World Health Organization. Coronavirus disease (COVID-19) outbreak, <u>https://www.who.int/</u> emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 9 March 2021).
- Zhang J, Wu S, Xu L. Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up. Biosci Trends. 2020/04/24. 2020; 14: 206–208. <u>https://doi.org/10. 5582/bst.2020.03069</u> PMID: <u>32321904</u>
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020/03/18. 2020; 34: 101623. <u>https://doi.org/10. 1016/j.tmaid.2020.101623</u> PMID: 32179124
- Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020/05/19. 2020; 167: 105941. https://doi.org/10.1016/j.rmed. 2020.105941 PMID: 32421537

- Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and Smoking. Nicotine Tob Res. 2020/04/04. 2020; 22: 1650–1652. https://doi.org/10.1093/ntr/ntaa059 PMID: 32242236
- Rodacki M. Severity of COVID-19 and diabetes mellitus: there is still a lot to be learned. Arch Endocrinol Metab. 2020/06/20. 2020; 64: 195–196. <u>https://doi.org/10.20945/2359-3997000000261</u> PMID: 32555983
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA Statement. Open Med. 2009/01/01. 2009; 3: e123–30. PMID: 21603045
- Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020/03/01. 2020; 7: 7. https://doi.org/10.1186/s40779-020-00238-8 PMID: 32111253
- Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. American journal of epidemiology. 1974; 99(5):325–32. Epub 1974/05/01. https://doi.org/10.1093/ oxfordjournals.aje.a121617 PMID: 4825599.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020/02/08. 2020; 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 PMID: 32031570
- Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020/02/23. 2020; 75: 1730–1741. <u>https://doi.org/ 10.1111/all.14238 PMID: 32077115</u>
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020/02/29. 2020; 382: 1708–1720. <u>https://doi.org/10.1056/</u> NEJMoa2002032 PMID: 32109013
- Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020/03/22. 2020; 92: 797–806. <u>https://doi.org/10.1002/jmv.25783 PMID: 32198776</u>
- Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. Yonsei Med J. 2020/05/12. 2020; 61: 431–437. https://doi.org/10.3349/ymj.2020.61.5.431 PMID: 32390367
- Zhang YT, Deng AP, Hu T, Chen XG, Zhuang YL, Tan XH, et al. [Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020/04/29. 2020; 41: E057. https://doi.org/10.3760/cma.j.cn112338-20200318-00378 PMID: 32340095
- 17. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020/04/29. 2020; 48: 543–551. https://doi.org/10.1007/s15010-020-01432-5 PMID: 32342479
- Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020/04/30. 2020; 20: 311. https://doi.org/10.1186/s12879-020-05010-w PMID: 32345226
- Zheng Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, et al. Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. Pharmacol Res. 2020/05/ 04. 2020; 157: 104821. https://doi.org/10.1016/j.phrs.2020.104821 PMID: 32360481
- Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis. 2020/05/04. 2020. <u>https://doi.org/10.1093/cid/ciaa539</u> PMID: 32361738
- Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020/04/03. 2020; 75: 1742–1752. <u>https://doi.org/10.1111/all.</u> 14309 PMID: 32239761
- Wang Y, Liao B, Guo Y, Li F, Lei C, Zhang F, et al. Clinical Characteristics of Patients Infected With the Novel 2019 Coronavirus (SARS-Cov-2) in Guangzhou, China. Open Forum Infect Dis. 2020/06/25. 2020; 7: ofaa187. https://doi.org/10.1093/ofid/ofaa187 PMID: 32577426
- Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, et al. Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis. 2020/05/24. 2020. https://doi.org/10.1093/cid/ciaa632 PMID: 32444880
- 24. Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther. 2020/05/26. 2020; 45: 609–616. https://doi.org/10.1111/jcpt.13170 PMID: 32449224
- Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020/04/11. 2020; 201: 1380–1388. https://doi. org/10.1164/rccm.202002-0445OC PMID: 32275452

- Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020/06/17. 2020; 3: e2012270. https://doi.org/10.1001/jamanetworkopen.2020. 12270 PMID: 32543702
- Cao Z, Li T, Liang L, Wang H, Wei F, Meng S, et al. Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One. 2020/06/20. 2020; 15: e0234764. https://doi.org/10.1371/ journal.pone.0234764 PMID: 32555674
- 28. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infect Dis. 2020/06/20. 2020; 20: 427. https://doi.org/10.1186/s12879-020-05128-x PMID: 32552751
- 29. Nie Y, Li J, Huang X, Guo W, Zhang X, Ma Y, et al. Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China. Int J Epidemiol. 2020/06/27. 2020. https://doi.org/10. 1093/ije/dyaa081 PMID: 32588051
- Zhang SY, Lian JS, Hu JH, Zhang XL, Lu YF, Cai H, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020/07/10. 2020; 9: 85. https://doi.org/10.1186/s40249-020-00710-6 PMID: 32641121
- Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020/05/16. 2020; 43: 1392–1398. https://doi.org/10.2337/ dc20-0576 PMID: 32409502
- Gregoriano C, Koch D, Haubitz S, Conen A, Fux CA, Mueller B, et al. Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis. Swiss Med Wkly. 2020/07/16. 2020; 150: w20316. https://doi.org/10.4414/smw. 2020.20316 PMID: 32668007
- 33. Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohammed HM, Abdelazez AA, et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample of ESNA Quarantine Hospital's Patients, Egypt: A Retrospective Study. Infect Drug Resist. 2020/08/09. 2020; 13: 2375–2383. https://doi.org/10.2147/IDR.S263489 PMID: 32765012
- 34. Yu C, Lei Q, Li W, Wang X, Li W, Liu W. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience. J Infect Public Heal. 2020/07/29. 2020; 13: 1202–1209. https://doi.org/10.1016/j.jiph.2020.07.002 PMID: 32718894
- Wang B, Wang Z, Zhao J, Zeng X, Wu M, Wang S, et al. Epidemiological and clinical course of 483 patients with COVID-19 in Wuhan, China: a single-center, retrospective study from the mobile cabin hospital. Eur J Clin Microbiol Infect Dis. 2020/07/20. 2020; 1–7. https://doi.org/10.1007/s10096-020-03927-3 PMID: 32683596
- Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. Int J Infect Dis. 2020/07/24. 2020; 98: 462–466. https://doi.org/10.1016/j.ijid.2020.07.017 PMID: 32702415
- Xu X, Yu MQ, Shen Q, Wang LZ, Yan RD, Zhang MY, et al. Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. Int J Med Sci. 2020/08/14. 2020; 17: 2052–2062. https://doi.org/10.7150/ijms.47935 PMID: 32788884
- 38. Wei Y, Zeng W, Huang X, Li J, Qiu X, Li H, et al. Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study. BMC Infect Dis. 2020/07/31. 2020; 20: 549. https://doi.org/10.1186/s12879-020-05252-8 PMID: 32727456
- Liu S, Luo H, Wang Y, Cuevas LE, Wang D, Ju S, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis. 2020/08/09. 2020; 20: 584. <u>https://doi.org/10.1186/s12879-020-05314-x</u> PMID: 32762665
- Wang Y, Zhou Y, Yang Z, Xia D, Hu Y, Geng S. Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China. Respiration. 2020/08/26. 2020; 1–9. https://doi.org/10.1159/000507940 PMID: 32841948
- Ishii M, Terai H, Kabata H, Masaki K, Chubachi S, Tateno H, et al. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study. J Infect. 2020/09/14. 2020. https://doi.org/10.1016/j.jinf.2020.08.052 PMID: 32920063
- 42. Shu Z, Zhou Y, Chang K, Liu J, Min X, Zhang Q, et al. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases. Front Med. 2020/09/15. 2020; 1–16. https://doi.org/10.1007/s11684-020-0803-8 PMID: 32926319
- 43. Du H, Pan X, Liu N, Chen J, Chen X, Werring DJ, et al. The effect of vascular risk factor burden on the severity of COVID-19 illness, a retrospective cohort study. Respir Res. 2020/09/23. 2020; 21: 241. https://doi.org/10.1186/s12931-020-01510-0 PMID: 32957997

- 44. Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC infectious diseases. 2020; 20(1):787. Epub 2020/10/24. https://doi.org/10.1186/s12879-020-05452-2 PMID: 33092539; PubMed Central PMCID: PMC7578439.
- 45. Lee SG, Park GU, Moon YR, Sung K. Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database. International journal of environmental research and public health. 2020; 17(22). Epub 2020/11/22. https://doi.org/10. 3390/ijerph17228559 PMID: 33218161; PubMed Central PMCID: PMC7698934.
- 46. Kim K, Choi JW, Moon J, Akilov H, Tuychiev L, Rakhimov B, et al. Clinical Features of COVID-19 in Uzbekistan. Journal of Korean medical science. 2020; 35(45):e404. Epub 2020/11/25. <u>https://doi.org/10.3346/jkms.2020.35.e404</u> PMID: 33230989; PubMed Central PMCID: PMC7683242.
- Ren L, Yao D, Cui Z, Chen S, Yan H. Corona Virus Disease 2019 patients with different disease severity or age range: A single-center study of clinical features and prognosis. Medicine. 2020; 99(49):e22899. Epub 2020/12/09. https://doi.org/10.1080/0886022X.2019.1605294 PMID: 31057017; PubMed Central PMCID: PMC7717834.
- Vial MR, Peters A, Pérez I, Spencer-Sandino M, Barbé M, Porte L, et al. Covid-19 in South America: clinical and epidemiological characteristics among 381 patients during the early phase of the pandemic in Santiago, Chile. BMC infectious diseases. 2020; 20(1):955. Epub 2020/12/16. https://doi.org/10. 1186/s12879-020-05665-5 PMID: 33317458; PubMed Central PMCID: PMC7734456.
- 49. Lv Z, Lv S. Clinical characteristics and analysis of risk factors for disease progression of COVID-19: A retrospective Cohort Study. International journal of biological sciences. 2021; 17(1):1–7. Epub 2021/01/ 05. https://doi.org/10.7150/ijbs.50654 PMID: 33390828; PubMed Central PMCID: PMC7757033.
- Zhang N, Zhang H, Tang Y, Zhang H, Ma A, Xu F, et al. Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study. International journal of medical sciences. 2021; 18 (4):921–8. Epub 2021/01/19. <u>https://doi.org/10.7150/ijms.51205</u> PMID: <u>33456349</u>; PubMed Central PMCID: PMC7807193.
- Zhang Q, Wang Z, Lv Y, Zhao J, Dang Q, Xu D, et al. Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China. Human cell. 2021; 34(2):419–35. Epub 2021/02/16. https:// doi.org/10.1007/s13577-021-00499-y PMID: 33586121; PubMed Central PMCID: PMC7882230.
- Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020/04/27. 2020; 81: e16–e25. <u>https://doi.org/ 10.1016/j.jinf.2020.04.021</u> PMID: 32335169
- Rahman A, Sathi NJ. Risk Factors of the Severity of COVID-19: a Meta-Analysis. medRxiv. 2020. https://doi.org/10.1111/ijcp.13916 PMID: 33372407
- 54. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020/03/25. 2020; 18: 20. https://doi.org/10.18332/tid/119324 PMID: 32206052
- 55. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2020/06/17. 2020. <u>https://doi.org/10.1016/j.ajic.2020.06.008</u> PMID: 32540370
- Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020/04/02. 2020; 130: 304–309. <u>https://doi.org/10.20452/pamw.</u> 15272 PMID: 32231171
- Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging Dis. 2020/06/04. 2020; 11: 668–678. https://doi.org/10.14336/AD.2020.0502 PMID: 32489711
- Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020/07/30. 2020; 99: 47–56. https://doi.org/10.1016/j.ijid.2020.07.029 PMID: 32721533
- 59. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020/03/ 17. 2020; 94: 91–95. https://doi.org/10.1016/j.ijid.2020.03.017 PMID: 32173574
- Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020/04/08. 2020; 34: 339–343. <u>https://doi.org/10. 23812/Editorial-Conti-3 PMID: 32253888</u>
- Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Hear J. 2020/05/11. 2020; 41: 1810–1817. <u>https://doi.org/ 10.1093/eurhearti/ehaa373</u> PMID: 32388565

- Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020/ 03/15. 2020; 8: e20. https://doi.org/10.1016/S2213-2600(20)30117-X PMID: 32171067
- 63. Silva A, Moreira JC, Martins SR. COVID-19 and smoking: a high-risk association. Cad Saude Publica. 2020/05/20. 2020; 36: e00072020. https://doi.org/10.1590/0102-311x00072020 PMID: 32428076
- Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020/04/05. 2020;9. https://doi.org/10.3390/jcm9030841 PMID: 32244852
- Desai R, Singh S, Parekh T, Sachdeva S, Sachdeva R, Kumar G. COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis. Diabetes Metab Syndr. 2020/05/22. 2020; 14: 683–685. https://doi.org/10.1016/j.dsx.2020.05.021 PMID: 32438333
- Desai R, Singh S, Parekh T, Sachdeva S, Kumar L, Sachdeva R, et al. COVID-19 and Shock: A Cautionary Tale for Elderly Patients From a Pooled Analysis. Ann Emerg Med. 2020/05/31. 2020; 75: 789–791. https://doi.org/10.1016/j.annemergmed.2020.04.014 PMID: 32471584
- Sharma A, Garg A, Rout A, Lavie CJ. Association of Obesity With More Critical Illness in COVID-19. Mayo Clin Proc. 2020/08/31. 2020; 95: 2040–2042. <u>https://doi.org/10.1016/j.mayocp.2020.06.046</u> PMID: 32861346
- Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pr. 2020/07/15. 2020; 14: 295–300. https://doi.org/10.1016/j.orcp.2020.07.002 PMID: 32660813
- Russell R. Covid-19 and COPD: A Personal Reflection. Int J Chron Obs Pulmon Dis. 2020/05/20. 2020; 15: 883–884. https://doi.org/10.2147/COPD.S255101 PMID: 32425514
- Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020/03/13. 2020; 109: 531–538. <u>https://doi.org/10.1007/s00392-020-01626-9 PMID: 32161990</u>
- Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005/05/18. 2005; 111: 2605–2610. <u>https://doi.org/10.1161/</u> CIRCULATIONAHA.104.510461 PMID: 15897343
- 72. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015/03/15. 2015; 19: 1965–1974. https://doi.org/10. 1111/jcmm.12573 PMID: 25766467
- 73. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and metaregression. J Renin Angiotensin Aldosterone Syst. 2020/05/16. 2020; 21: 1470320320926899. <u>https:// doi.org/10.1177/1470320320926899</u> PMID: 32408793
- 74. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005/07/08. 2005; 436: 112–116. <u>https://doi.org/10.1038/nature03712 PMID: 16001071</u>
- 75. Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pr. 2020/04/03. 2020; 162: 108132. https://doi.org/10.1016/j.diabres.2020.108132 PMID: 32234504
- 76. Giannakoulis VG, Papoutsi E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 2020/06/09. 2020; 6: 799–808. <u>https:// doi.org/10.1200/GO.20.00225 PMID: 32511066</u>
- 77. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020/04/16. 2020; 146: 110–118. <u>https://doi.org/10. 1016/j.jaci.2020.04.006 PMID: 32294485</u>
- Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013/05/31. 2013; 3: 957–976. https://doi.org/10.1002/cphy.c120028 PMID: 23720336
- 79. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020/05/21. 2020;5. <u>https://doi.org/10.3390/tropicalmed6010005</u> PMID: 33383742
- Kulkarni A V, Kumar P, Tevethia H V, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020/07/09. 2020; 52: 584–599. https://doi.org/10.1111/apt.15916 PMID: 32638436
- Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020/04/25. 2020; 18: 1548–1555. https://doi.org/10.1111/jth.14872 PMID: 32329246

- 82. Choudhury R, Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, et al. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg. 2020/04/22. 2020; 15: 29. https://doi.org/10.1186/s13017-020-00305-4 PMID: 32312290
- Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020/04/09. 2020; 18: 1752–1755. https://doi.org/10.1111/jth.14828 PMID: 32267998
- Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020/06/14. 2020; 46: 1339–1348. https://doi.org/10. 1007/s00134-020-06153-9 PMID: 32533197
- Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes care. 2019; 42(Suppl 1):S13–s28. Epub 2018/12/19. https://doi.org/10.2337/dc19-S002 PMID: 30559228.